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ABSTRACT

Common, complex diseases such as cardiovascular disease (CVD) represent an intricate
interaction between environmental and genetic factors and now account for the leading
causes of mortality in western society. By investigating the genetic component of
complex disease etiology, we have gained a better understanding of the biological
pathways underlying complex disease and the heterogeneity of complex disease risk.
However, the development of high throughput genomic technologies and large wellphenotyped multi-ethnic cohorts has opened the door towards more in-depth and transdisciplinary approaches to studying the genetics of complex disease pathogenesis.
Accordingly, we sought to investigate select complex traits and diseases using both
established and novel genomic technologies, including candidate gene resequencing,
high-throughput targeted microarray genotyping and candidate variant genotyping. We
demonstrate that a private and common variant, p.G116S, within the low-density
lipoprotein receptor (LDLR) gene among Inuit descendants has a large effect on plasma
cholesterol; that variation in cardio-metabolic and Alzheimer disease (AD) loci is not
associated with susceptibility to the pre-dementia phenotype known as “cognitive
impairment, no dementia”; and that established type 2 diabetes (T2D) variants are not
associated with T2D susceptibility among select aboriginal Canadian and Greenland
cohorts. Together, these studies represent a selection of established and novel genomic
strategies for the investigation of complex disease genetics which are likely to remain
fundamental in the continued investigation of complex disease pathogenesis.
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CHAPTER 1

INTRODUCTION

This chapter is based on material from the following publications: (1) Dube, J.B., and
Hegele, R.A. (2012). Genetics 100 for cardiologists: basics of genome-wide association
studies. Can J Cardiol 29, 10-17; and (2) Dube, J.B., Johansen, C.T., and Hegele, R.A.
(2011). Sortilin: an unusual suspect in cholesterol metabolism: from GWAS
identification to in vivo biochemical analyses, sortilin has been identified as a novel
mediator of human lipoprotein metabolism. Bioessays 33, 430-437.

1.1 Human disease

The concept of human disease can be briefly defined as dysfunction or abnormality in
biological function which enhances mortality and morbidity risk. As medical science has
advanced, preventive strategies have largely mitigated many of the risk factors
underlying the once common infectious diseases in developed nations. Although
historically notorious diseases such as the bubonic plague are no longer a leading cause
of death, a new class of diseases has risen to represent the top causes of mortality in the
developed world. Chronic non-infectious diseases that become clinically recognizable in
adulthood have reached prevalence worldwide as in correlation with longer average
lifespan. Diseases such as cancers, heart disease and stroke now account for a major
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percentage of deaths worldwide and thus pose the greatest threat to modern global public
health (Lozano et al., 2013).

1.1.1 History of human disease
In recent history, the most prominent diseases were infectious in nature and were often
linked to hygienic deficiencies. The plague of the 14th century, one of the world’s greatest
epidemics, was caused by the insidious spread of Yersinia pestis by fleas and rats (Ligon,
2006). Tuberculosis, another bacterial disease which reached epidemic proportions in
Europe during the Industrial Revolution, is believed to have been largely transmitted
through unpasteurized milk and milk products (Donoghue, 2009). Discoveries in
antibiotics, improved hygienic and sanitary practices as well as technological
advancements have since helped to limit epidemics of infectious disease. As these
advances have dramatically decreased early life mortality and have supported a longer
average lifespan among Western countries, the leading causes of mortality are now
represented by chronic age-related diseases (Figure 1.1). In North America, cancer, heart
disease and stroke cumulatively account for almost half of all reported deaths (Heron,
2012). Dementia and cognitive impairment, both of which are highly correlated with age,
are anticipated as the next epidemics to emerge over the coming decades. As these agerelated diseases represent major public health concerns, understanding the etiologies and
risk factors underlying common diseases has become a global imperative.

3

Figure 1.1 Historic rates of leading causes of death in the United States from 19001998. Data presented here were taken from the U.S. National Center for Health Statistics
(Centers for Disease Control and Prevention, 2009).
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1.1.2 Heritability of disease
Diseases may be distinguished based on the mode of disease transmission. Fundamental
classifications have characterized diseases as communicable and non-communicable
based on the respective presence or absence of a pathogenic microorganism necessary for
disease transmission. However, a crucial distinction in disease classification was the
observed inheritance of diseases or traits in offspring following mathematical ratios as
per Mendel’s early studies in peas. Pedigrees charting the inheritance of traits within a
family tree helped conceptualize a novel means for the transmission of disease
susceptibility via heritable or genetic factors. The heritability of a wide range of traits and
diseases has been explored through family-based studies that looked at phenotypic
heritability between related individuals who consequently were less genetically
heterogeneous compared to the general population. Studies comparing large sets of twin
pairs were also important as concordance rates between monozygotic twins who are
genetically identical could also be used in estimating the heritability of diseases. More
recently, genetic studies have expanded to large cohorts representative of the general
population where genetic heterogeneity is greatest. Intriguingly, family and twin studies
have ascribed strong heritability estimates to the cardio-metabolic traits relating to heart
disease as well as cognitive disorders such as Alzheimer disease (AD) (Mangino and
Spector, 2012).

1.1.2.1 Monogenic disease
In rare cases, diseases have been observed to segregate predictably and according to
Mendelian ratios among offspring. Through early genetic mapping approaches, which are

6

discussed later, it was shown that a single genetic variant of deleterious effect was
sufficient to cause remarkably penetrant and pathogenic phenotypes. Furthermore, the
variants underlying Mendelian diseases tended to disrupt the function of a single locus or
gene which led to the concept of monogenic diseases. Regarding specific modes of
inheritance, monogenic diseases can be inherited in an autosomal recessive manner in
which two dysfunctional alleles must be inherited for the disease phenotype to manifest.
Alternatively, monogenic diseases can be inherited in an autosomal dominant or codominant manner whereby a single dysfunctional allele can cause the disease phenotype
or two dysfunctional alleles can create an even more severe phenotype. Additional modes
of inheritance include sex-linked patterns of heritability. As monogenic diseases
exemplify the biological effects as a result of disrupting individual genes, this class of
genetic disease has been invaluable in helping improve our understanding of the genetic
architecture underlying many diseases and clinically-important traits currently
documented in the Online Mendelian Inheritance in Man database (OMIM) (Hamosh et
al., 2005).

1.1.2.2 Complex disease
In contrast to monogenic diseases, where a single variant is sufficient to cause a disease
phenotype, complex diseases represent a greater interaction between environmental and
genetic factors. No single genetic variant is sufficient to cause a complex disease
phenotype but rather multiple variants of low penetrance at multiple loci contribute
synergistically to modulate disease susceptibility. The leading model for complex
diseases is described as the common disease-common variant (CDCV) hypothesis which
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predicts that multiple commonly occurring variants from multiple genes individually
contribute a small effect on disease susceptibility but additively exert a considerable
effect in the manifestation of complex disease (Reich and Lander, 2001). An emerging
hypothesis has incorporated the potential contribution of rare variants of proportionately
larger effect on complex disease susceptibility; however, this concept is currently being
assessed for validity in the most common complex diseases (Pritchard, 2001). In support
of the heterogeneous nature of complex disease susceptibility, complex diseases are not
inherited according to the models which apply to monogenic diseases. Instead, common
variants are believed to contribute to the overall picture of disease susceptibility.

1.1.2.3 Disease penetrance
The phenotypic spectrum that exists within complex polygenic diseases, in terms of
characteristics such as disease severity and age of onset, is mediated by the complex
interaction between environmental and genetic risk factors. For certain complex diseases,
disease susceptibility is greatly modulated by variants with highly penetrant effects such
as hereditary forms of breast and ovarian cancer linked with mutations in the genes
encoding breast cancer 1 (BRCA1) and 2 (BRCA2) (Apostolou and Fostira, 2013). While
these large-effect variants are not deterministic of disease, it is important to note that
single variants can mediate patterns of inheritance similar to monogenic diseases.
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1.2

Genetic variation

The human and chimpanzee genomes differ by only ~4% which is remarkable
considering apparent physical distinctions (Varki and Altheide, 2005). In a more focused
comparison, any two humans share ~99.5% genomic similarity and yet people vary
considerably in terms of characteristics such as anthropometric measurements, eye or hair
colour (Tishkoff and Kidd, 2004). Genetic variation represents the small percentage of
genomic divergence and substantially contributes to the range of anthropometric traits we
observe in human populations. The approaches currently used to study genetic variation
are the result of the Human Genome Project which provided the first draft sequence of
the human genome as well as the efforts of international consortia such as the
International HapMap Project and the 1000 Genomes Project that developed a detailed
map of genetic variation throughout the human genome (2003). As one of the most
crucial tools to emerge from the genomic era, the comprehensive catalogue of genetic
variation in humans has facilitated unprecedented analyses of the role of genetic variation
in modulating various phenotypes and disease susceptibilities with novel applications
continuously emerging.

1.2.1 Classes of genetic variation
Several types of genetic variants comprise the ~0.5% of inter-individual genetic
divergence and are classed in terms of size and frequency. The various classes of
observed genetic variation are well documented and may vary considerably from largescale variation in the number of copies of entire chromosomes such as trisomy of
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chromosome 21 in Down syndrome to smaller-scale variation in the case of single base
substitutions or single nucleotide variants (SNVs). SNVs represent the most abundant
form of genetic variation and may potentially affect gene expression or protein structure
based on localization. SNVs are distinguished based on the frequency with which they
are observed in a population. Rare SNVs are observed with <1% frequency, uncommon
SNVs occur with 1%-5% frequency and common SNVs are observed with frequencies
>5%. Common SNVs, or single nucleotide polymorphisms (SNPs), have become
established as important markers in genomic mapping strategies based on the global
prevalence of these variants as well as the genome-wide coverage that the >38 million
validated SNPs offers.

1.2.2 Effect-frequency relationship
Based on the genetic models of monogenic and complex diseases, a distinct trend has
been observed between variant frequency and the variant-associated effect on disease risk
(Figure 1.2). The frequency of causative variants underlying monogenic diseases tends to
be extremely rare as these variants are subjected to heavy selective pressure and are thus
not likely to be propagated in subsequent generations. At the opposite end of the
frequency spectrum, SNPs have been subjected to low selective pressure due presumably
to small phenotypic effects and have thus reached relatively high frequencies in global
populations. The implications of this frequency-effect trend strongly influenced our
concept of rare and common disease, which led to the development of the CDCV
hypothesis. As common variation has been widely hypothesized to account considerably
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Figure 1.2 Inverse relationship between variant frequency and variant effect size.
Studies on rare monogenic disorders and common, complex diseases have supported the
correlation between variant frequency and effect size whereby rare variants tend to
associate with large and often deleterious effects while common variants are more likely
to have subtle effects on disease susceptibility. Modified from Manolio et al. (2009).
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for the prevalence of common and complex disease, SNPs have been established as the
genomic marker of choice for the majority of studies emerging from the genomics era.

1.2.3 Linkage disequilibrium
The concept of independent assortment was a fundamental assumption in Mendel’s
studies of peas in which the heritable factors underlying traits were passed on to offspring
independently of each other. This concept is applicable for variants separated by
considerable distance or located on different chromosomes; however, in the case of SNPs
that are present every ~300 bases, SNP alleles spanning a limited physical range tend to
be inherited together as clusters known as haplotype blocks through a phenomenon called
linkage disequilibrium (LD) (Gabriel et al., 2002). Through the genotyping of millions of
SNPs in multi-ethnic populations, the International HapMap Project created a
comprehensive map of haplotype block structures across the human genome as well
asestimates of LD between variants, which have permitted the reliable prediction or
imputation of variant genotypes. By imputing SNP genotypes, it is possible to vastly
expand genomic coverage while sparing the costs of directly genotyping potentially
millions of supplemental markers.

1.2.4 Hardy-Weinberg equilibrium
Another important characteristic of variant frequencies involves the allelic distribution
for a given variant. SNPs are most often bi-allelic which means for any SNP there exists
a major allele that represents >50% of all alleles specific to that SNP in a given
population while the minor allele represents the remaining percentage. As part of the
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CDCV hypothesis, SNPs are believed to individually contribute small effects towards
disease susceptibility. Accordingly, the relative frequencies of homozygotes and
heterozygotes for a given SNP genotype should remain stable from generation to
generation. The Hardy-Weinberg equilibrium (HWE) principle is represented in a
mathematical equation for calculating expected genotype frequencies for a biallelic
variant, assuming the absence of such influences on allele frequency including genetic
drift, natural selection or non-random mating (Mayo, 2008). Thus comparability between
observed and expected genotype frequencies using HWE tests a fundamental assumption
of the CDCV hypothesis. More recently, large-scale genotyping studies have used HWE
as a means of statistical quality control in detecting potential genotyping errors by the
variants that deviate substantially from HWE genotype proportions (Pearson and
Manolio, 2008).

1.3 Approaches to studying genetic disease

The various approaches to studying the genetics of complex diseases have evolved in
parallel with the development of genomic technologies. In the pre-genomic era,
correlations were investigated between patients and clinically important variables such as
weight, lipid profile or blood type. While these clinical characteristics served in part as
surrogates for genetic variants, the first studies to directly investigate genetic diseases
were based on families affected by predictably segregating disease phenotypes. The
progression to population genetics studies came with a host of novel technological and
statistical approaches aimed at testing variant-disease association in large genetically
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diverse cohorts. Interestingly, as new technologies have been integrated in the field of
medical genetics, the strategies of family- and population-based studies have remained
fundamental to the ongoing study of genetic susceptibility to complex disease.

1.3.1 Family-based techniques
As the traditional approach to studying disease genetics, family-based studies have been
important in identifying the genetic architecture of highly penetrant and monogenic
phenotypes. Linkage analysis represents the established approach for assessing the
cosegregation of trait loci specifically within families (Dawn Teare and Barrett, 2005).
Methodologically, linkage analyses are best suited to the study of monogenic diseases in
which a highly penetrant mutation underlies disease susceptibility. Statistical power is
also derived from the exclusive study of family members where genetic variation
between individuals will be minimal thus lowering the false-positive discovery rate or
type 1 error. As technology advanced, linkage analyses replaced genetic markers with
SNPs to increase resolution for mapping disease loci. Complex diseases are not ideally
suited for linkage analyses based on the greater genetic heterogeneity, smaller effect sizes
and environmental interactions which confound the strength of potential linkage signals.
Furthermore, linkage analyses assume specific modes of inheritance which are not
applicable to complex diseases (Pollex and Hegele, 2005).

1.3.2 Population-based techniques
Genetic analyses of the common complex diseases require population-based cohorts
where genetic and phenotypic heterogeneity is high. Thus, in the study of complex
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disease the traditional approaches used in family-based studies have been replaced by
new techniques for identifying disease-related loci. Candidate gene studies represented
the first attempt to test for association between genetic variation and disease
susceptibility by sequencing genes known a priori to be involved in complex disease
etiology. Associations identified using this approach suffered from lack of replication in
follow-up studies which suggested the need to address the presence of confounding
factors.

Genome-wide association studies (GWAS) have become established as an
effective and unbiased approach for identifying associations between common genomic
variants and complex traits or diseases (Attia et al., 2009; Dube and Hegele, 2012). In
this approach, millions of SNPs scattered across the genome are genotyped in a large
population using commercially available SNP genotyping arrays. Each individual SNP
genotype is then tested for association with discrete case-control status or with a
quantitative trait such as plasma cholesterol concentration (Figure 1.3). SNP associations
are then used as proxies for large haplotype blocks, which implicate a locus with disease
susceptibility. As GWAS-identified SNPs most commonly lie in non-coding or intergenic
regions, biological relevance is hypothesized based on the genes within the locus with
less emphasis on the role of the associated variant. More recently, targeted GWAS have
emerged in which custom SNP genotyping arrays are populated with variants that have
been previously associated with a disease or trait. The latest targeted GWAS platforms
include the Cardio-Metabochip which genotypes common variants associated with
various cardio-metabolic traits (Voight et al., 2012). Similarly, the Immunochip
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Figure 1.3 Framework for a genome-wide association study. A) The human genome
is >99% invariant, but at approximately every 300 nucleotide bases along the DNA
string are well-characterized nucleotide sites that vary among people; these sites toggle
between 1 of 2 naturally occurring options. For instance, in a pool of individuals, the
more common DNA “letter” at a polymorphic site might be “A” for adenosine, and a
minority of chromosomes contain the less common form, “C” for cytosine. Such
variations are called “single nucleotide polymorphisms” (SNPs). B) At each defined SNP
site, people have a genotype composed of 2 alleles—1 from each parent—a feature
detected with a chemical genotyping method as shown. Each dot on the grid is the SNP
genotype for 1 person. Three clusters of people are seen: 2 varieties of homozygotes,
namely A/A and C/C, and heterozygotes, namely A/C. It is reasonable to ask whether the
members of 1 genotype class differ from those of another. In a candidate gene study, the
SNP is deliberately chosen to mark a gene hypothesized a priori to play a mechanistic
role determining the trait, but in a genome-wide association study, SNPs from across the
entire genome are studied agnostically, without premeditation regarding their possible
function. C) For case-control studies, SNP genotyping as in B) is performed in cases
(filled symbols [circles are female, squares are male]) and matched controls. D) Odds
ratios (ORs) are calculated and displayed on a forest plot: the OR provides an estimate of
the risk of conferred by an allele of a given SNP. An allele with an OR >1.0 is associated
with increased probability of case status in carriers of the allele and is thus identified as
the risk allele. The genotypic ORs for several cohorts can be combined to provide an
overall OR for a meta-analysis. E) Alternatively, for a quantitative trait association study,
SNP genotyping as in B) is performed in a sample of the general population. F) Linear
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regression is used to model the relationship between SNP genotypes and the quantitative
trait measurement that provides an estimation of effect size, or β-coefficient, and P-value.
The β-coefficient indicates the change in the quantitative trait measurement per copy of
the associated allele and is given in the same units as the trait. This figure was reproduced
with permission (Dube and Hegele, 2012).

18

19

facilitates the genotyping of variants associated with immunologic pathways (Cortes and
Brown, 2011). Since the first published GWAS in 2008, nearly 1500 GWAS have been
published on a range of complex diseases, identifying both expected and novel loci in
complex disease pathways.

1.3.2.1 Statistics in GWAS
GWAS implementation requires an understanding of several statistical concepts. Firstly,
the concept of statistical power is crucial in GWAS design. Statistical power establishes
the probability of rejecting the null hypothesis, or no genotype-phenotype association,
when no true association exists. Power is calculated based on a given threshold for
significance, sample size, the anticipated SNP effect size on disease risk as well as the
frequency of the risk-associated variant. Power calculations can help determine the
sample size required to detect an association or, conversely, power can be used to assess
the effect sizes that can be identified as true association for a given sample size.

Secondly, the tests for association used in GWAS depend upon the phenotype
being studied. Discrete phenotypes such as disease status utilize multivariate logistic
regression whereas quantitative phenotypes are studied using multivariate linear
regression. In either approach, an additive model is calculated to fit the correlation
between genotype and phenotype and a P-value is generated which reflects the accuracy
of this model. For discrete phenotypes, an odds ratio (OR) is also calculated which
provides the frequency ratio for the disease-associated allele in cases versus controls. For
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quantitative traits, the calculated β coefficient represents the effect size per allele copy
and is given in the units of the trait.

Another important consideration involves the determination of the threshold of
significance. Significance, as indicated by the P-value, derived from each test for
association provides a measure of the strength of association. Because millions of SNPs
are being simultaneously tested for association, the standard false-positive rate of 5% is
considered inadequate as a GWAS of one million SNPs will expectedly yield 5x104 false
positive associations. Thus a Bonferroni-corrected threshold of significance is applied
where the standard P-value of 0.05 is divided by the number of SNPs being tested for
association. In the case of a GWAS utilizing one million SNPs, the Bonferroni-adjusted
P-value would be 5x10-8; any P-values below this threshold are thus considered
statistically significant.

Quality control measures used in GWAS also require statistical context.
Particularly in GWAS of discrete phenotypes, it is important to limit the presence of any
population substructure or stratification that may create spurious associations. Unequal
proportions of individuals from different populations, such as multi-ethnic cohorts, may
create differences in allele frequency independent of disease status. In order to address
potential population stratification, the case population should not differ significantly from
the control population in terms of demographic composition which includes potentially
confounding characteristics such as age or sex. It is also preferable to investigate
participants of a single ethnicity in order to limit ethnicity-related genetic variation.
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Statistically, principal component analysis and genomic control are two widely
implemented approaches to address population stratification (Price et al., 2006).

1.3.3 Resequencing studies
In the wake of GWAS, there has been increasing interest in resequencing GWASidentified loci in order to identify low-frequency variants with potentially larger effect
sizes on disease susceptibility. As this approach is focused on rare variants, it will be
difficult to test for association in the manner applied with GWAS. Thus studies compare
the accumulation of rare variants at targeted loci in case and control populations.
Imputation of rare variant genotypes using publicly available GWAS data sets has been
used to expand the effective sample size and facilitate association testing between rare
variants and disease status (Johansen et al., 2010).

1.3.4 Association studies across ethnicities
Replication of disease-variant associations remains the gold standard for validating
GWAS findings. As GWAS have been heavily weighted towards populations of northern
European ancestry, replication of the top GWAS findings in multi-ethnic cohorts has
become an important stage in GWAS validation (Cooper et al., 2008). The inclusion of
well-defined multi-ethnic populations in GWAS incorporates a greater range of human
genetic diversity defined by differences in both allele frequencies and LD patterns via
varying haplotype block structures. Genotype-phenotype associations that are
consistently observed in multi-ethnic studies provide increased confidence behind
putative disease loci. Ethnicity-specific differences in allele frequencies, while potentially
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confounding, may also help to identify novel disease loci that may not have reached
genome-wide significance in other studies simply due to low allele frequencies and thus
limited statistical power (Pulit et al., 2010).

1.3.5 Genetic studies in population isolates
Population isolates represent populations that grew from a small group of founders. Due
to a combination of geographic or cultural isolation as well as additional forms of genetic
drift such as population bottlenecks, genetic diversity within population isolates is
significantly lower than the genetic diversity observed in the general population (ArcosBurgos and Muenke, 2002). Well-known population isolates such as the Old Order
Amish and the Finnish have been studied extensively in genetic mapping studies of
heritable phenotypes and have revealed several advantages to genetic mapping studies in
population isolates (Peltonen et al., 2000). Firstly, the limited genetic heterogeneity
within population isolates provides a statistical advantage to detecting association signals
as discussed earlier. Given the limited genetic heterogeneity as a result of the founder
effect, inbreeding within population isolates is virtually unavoidable and enhances the
prevalence of recessive disorders through loss of heterozygosity. Secondly, population
isolates are exposed to similar environmental and cultural factors; a crucial characteristic
which limits the effect of potentially confounding environmental factors. Thirdly, welldocumented multi-generational pedigrees have been documented in many population
isolates which facilitates linkage analysis. Population isolates are also well-suited for the
study of complex phenotypes for the same reasons that have made them ideal for the
study of Mendelian disorders (Kristiansson et al., 2008). The application of GWAS to
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population isolates has presented an alternative and statistically favourable method for
identifying novel disease loci.

1.4 Genetic architecture of select human diseases

Common complex diseases now account for the leading causes of mortality in Western
society and cardiovascular disease (CVD) ranks among the top three. While CVD can be
studied using downstream major events, such as myocardial infarction, it is also
important to study the genetics of CVD risk factors in order to piece together the various
mechanisms that modulate CVD risk. Thus, studies on clinically important variables,
such as plasma lipid profile, which is largely determined by genetic factors (Hegele,
2009), have contributed greatly to our understanding of predisposition to CVD. Another
highly prevalent CVD co-morbidity in Western society is type 2 diabetes mellitus (T2D).
Twin and family studies have similarly ascribed a significant genetic component in T2D
susceptibility, which has made T2D the focus of large-scale multi-ethnic GWAS
(Imamura and Maeda, 2011). Dementia-related diseases in the elderly are also anticipated
to dramatically rise with the aging population, which has inspired intense investigation
into the causes of common conditions such as AD which is believed to be considerably
heritable. Together, these diseases represent major public health concerns where genetic
analyses can contribute significantly to treatment and prevention strategies.
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1.4.1 Familial hypercholesterolemia
Familial hypercholesterolemia (FH, OMIM 143890) is an autosomal dominant disease in
which dysregulation of low-density lipoprotein (LDL) homeostasis leads to drastically
elevated plasma LDL concentrations, and results in premature atherosclerosis and
coronary heart disease (CHD) (Liyanage et al., 2011). FH has played an important role in
developing our understanding of CVD risk factors, as the markedly elevated LDL
cholesterol (LDL-C) levels implicated plasma cholesterol in CVD susceptibility.
Subsequent research has characterized the process of atherosclerosis as a complex system
involving lipid accumulation in artery walls and chronic inflammation (Lusis, 2000).
Through FH studies, it was established that severely elevated plasma cholesterol was
sufficient to enhance atherosclerosis, thus establishing plasma cholesterol and LDL-C as
robust CVD risk factors in the general population.

1.4.1.1 Pathophysiology and genetic architecture
Clinical diagnosis of FH varies but typically includes childhood presentation of
xanthomas and LDL cholesterol (LDL-C) >95th percentile (Raal and Santos, 2012). As
described by Brown and Goldstein in their Nobel Prize-winning research (Goldstein and
Brown, 2009), the elevated plasma LDL-C observed in FH is due to variation in the gene
encoding the low-density lipoprotein receptor (LDLR); a cell surface receptor that binds
and internalizes circulating LDL particles. Rare loss-of-function LDLR mutations impair
plasma LDL homeostasis leading to hypercholesterolemia and the accelerated formation
of atherosclerotic plaques. While mutations in LDLR account for the majority of FH
cases,

mutations

in

the

APOB

and

PCSK9

genes

also

produce

similar
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hypercholesterolemia phenotypes (Raal and Santos, 2012). Interestingly, heterozygous
FH (HeFH) is quite common for a monogenic disease. HeFH is generally observed at a
frequency of 1:500 but has been reported at much higher frequencies in specific founder
populations such as Dutch South Africans where HeFH frequency is reportedly 1:70; the
frequency of homozygous FH (HoFH) in the general population is considerably lower at
1:106 (Liyanage et al., 2011).

1.4.1.2 Plasma cholesterol as a complex trait
The genetic basis for most Mendelian dyslipidemias such as FH has been solved while
our understanding of the genetic variation underlying common lipid trait variance in the
general population remains incomplete. Through the application of GWAS to lipoprotein
concentration in

population-based samples,

genes

associated with Mendelian

dyslipidemias have also been associated with the variance in lipid concentration observed
in the general population. For example, common variants in LDLR, APOB and PCSK9
have all been highly associated with plasma LDL concentration in the largest GWAS
meta-analysis on plasma lipid traits (Teslovich et al., 2010). Perhaps more interestingly,
novel and unexpected LDL-C-associated loci have emerged such as the SORT1 locus
which has subsequently been validated as a mediator of plasma LDL concentration by
binding and internalizing circulating apoB-containing lipoproteins (Dube et al., 2011). A
major caveat, however, relates to the fact that only a modest portion of variance in LDL
concentration has been attributed to common variation (Willer and Mohlke, 2012). While
a portion of the body’s cholesterol is derived from the environment, the overwhelming
portion of the cholesterol pool is synthesized endogenously and is thus anticipated to be
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largely genetically determined (Hegele, 2009). One estimate ascribed 50% heritability to
plasma LDL concentration which can be contrasted against the ~25-30% variance
explained by genetic variation at 95 loci (Perusse et al., 1997; Teslovich et al., 2010).
Resequencing of GWAS-identified genes for the detection of additional common and rare
variants has been shown to increase the portion of explained heritability in LDL
concentration and supports the execution of large-scale whole genome sequencing efforts
in the future (Sanna et al., 2011).

1.4.2 Late-onset cognitive decline and dementia
More than 300 psychiatric disorders have been described where an established
mechanism of pathogenesis is often absent (Sullivan et al., 2012). With the growing
elderly population, there has been concern regarding the anticipated rise in geriatric
psychiatric disorders, our ability to treat these disorders as well as the greater burden that
will be placed on already exhausted healthcare expenditure. By studying the genetics of
heritable late-onset psychiatric disorders, it may be possible to dissect the biological
pathways that modulate a phenotype as complex as cognitive health and to develop early
diagnostic and intervention strategies.

1.4.2.1 Spectrum of disease severity
Dementia represents a common end-point for many psychiatric disorders and affects ~5%
of the elderly (Eaton et al., 2008). Accordingly, the clinical definition broadly includes
impairment in memory as well as at least one other cognitive domain which includes
language, calculations, orientation and judgment. Importantly, the cognitive loss must be
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of sufficient severity as to significantly disable social or occupational autonomy.
Cognitive testing scores are also used to measure and track the state of the patient’s
cognitive health (Kawas, 2003). Although cognitive decline is associated with normal
aging, the observed cognitive deficits are not severe enough to interfere with the patient’s
autonomy. As cognitive impairment in the elderly is considered to be a degenerative
process, it is widely believed that a period of intermediate yet measurable cognitive
impairment precedes dementia and has been described as “cognitive impairment, no
dementia” (CIND) or mild cognitive impairment (MCI) (Graham et al., 1997). The major
distinction between CIND and MCI involves the more inclusive definition of CIND
which is based on the exclusion of dementia and clinical evidence of any form of
cognitive impairment (Graham et al., 1997); MCI is specific to pre-dementia where AD is
suspected (Voisin et al., 2003). Both CIND and MCI have frequencies of ~20% among
the elderly with CIND patients 5 times more likely to develop dementia while 10% - 15%
of MCI patients progress to AD (Tarawneh and Holtzman, 2012; Tuokko et al., 2003).
Logistically, pre-dementia studies have been fraught by phenotypic heterogeneity as
patients can progress to dementia, remain stable or improve cognitively.

1.4.2.2 Alzheimer disease
AD is by far the most prevalent cognitive disease affecting elderly people >65 years old.
Among the elderly, AD underlies >70% of dementia cases and represents the sixth
highest cause of death across all ages in the United States (Tarawneh and Holtzman,
2012). Twin studies have also ascribed considerable heritability in AD with estimates
ranging from 58% - 79% (Gatz et al., 2006). Genetic studies in AD hit a major
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breakthrough when autosomal dominant mutations in amyloid beta precursor protein
(APP), presenilin 1 (PSEN1) and 2 (PSEN2) were shown to cause the rare early-onset
form of AD (Tanzi, 2012). GWAS on the more prevalent late-onset form of AD
identified apolipoprotein E (APOE) as a candidate gene. Additional susceptibility loci
implicated immune and inflammatory pathways as well as lipid trafficking pathways.
Cumulatively, common variation is estimated to explain ~33% of the genetic risk. Based
on GWAS findings, the potential roles of immunity, inflammation and lipid metabolism
in AD pathogenesis provide new perspectives to approach AD risk which may help
inform future genetic strategies for studying AD.

1.4.2.3 Vascular dementia
Vascular dementia (VaD) refers to dementia resulting from cerebrovascular dysfunction
and accounts for ~16% of dementia cases in the elderly (Ott et al., 1995).
Cerebrovascular dysfunction can manifest as subclinical brain injury, silent brain
infarction or stroke; all of which contribute toward a damaging environment of chronic
ischemia in the brain. Twin studies have shown little support for a significant heritable
component in VaD and, perhaps not surprisingly, GWAS on VaD have failed to return
genome-wide significant results. Although genetic approaches to studying VaD have not
been encouraging, they have also been hampered by the phenotypic heterogeneity
underlying VaD. Additionally, alternative approaches may be useful in studying VaD
susceptibility which includes investigating the genetics of known VaD risk factors. It is
also well-known that the cardio-metabolic dysfunction that enhances atherosclerosis and
CVD in the periphery correlates with cognitive health in that CVD risk factors such as
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lipid profile, obesity and T2D have each been linked with enhanced risk of cognitive
decline (Gorelick et al., 2011). Thus an approach focused on genetic variation at cardiometabolic loci in VaD may shed new light on predisposition to cognitive decline.

1.4.3 Type 2 diabetes
Diabetes broadly refers to a group of metabolic diseases defined by abnormal plasma
glucose homeostasis. T2D is the most prevalent form of diabetes and is clinically
characterized by hyperglycemia, insulin resistance and impaired insulin secretion (Patel
and Macerollo, 2010). According to a World Health Organization study, T2D had a
worldwide prevalence of 2.8% across all age groups in 2000, which accounted for 171
million people (Wild et al., 2004). T2D has devastating long-term effects on the body
such as macrovascular and microvascular complications as well as effects on lipid
homeostasis. Accordingly, T2D has been strongly implicated as an independent risk
factor for CVD (Wilson, 1998; Wilson et al., 1998). As a complex disease, T2D risk is in
part mediated by lifestyle and environmental factors which can be managed. The genetic
aspect of T2D susceptibility, however, has helped reveal some of the biological pathways
underlying T2D pathogenesis which may be targeted for therapeutic intervention.
Considering that ~65% of diabetics die from CVD-related causes, improved
understanding and treatment of T2D may have a significant impact on improving patient
quality of life (Grundy et al., 1999).
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1.4.3.1 Pathophysiology
T2D pathogenesis is driven largely by 1) dysfunctional pancreatic β cells which produce
and secrete insulin; 2) excess hepatic glucose production; and 3) insulin resistance where
insulin-mediated glucose clearance is disrupted (Leahy, 2005). Insulin represents the key
hormone responsible for maintaining glycemic control where insulin secretion supports
normoglycemia (Stumvoll et al., 2005). Prior to T2D, patients develop progressive
insulin resistance where the glucose-lowering effects of insulin are gradually impaired
and normal glycemic homeostasis is disrupted leading to hyperglycemia. β cell function
ramps up in order to compensate for the insulin insensitivity which leads to observed
hyperinsulinemia. With chronic and worsening hyperglycemia, the β cell cannot maintain
the high rate of insulin secretion. Thus β cell function and mass both deteriorate as the
disease progresses which further contributes to the dysregulation of glycemic
homeostasis (Leahy, 2005). Together, the chronic dysregulation of glycemic homeostasis
is manifested as major complications such as diabetic retinopathy, nephropathy and
neuropathy.

1.4.3.2 Common genetic risk factors
As with many common complex diseases, family and twin studies suggested a strong
heritable component in T2D susceptibility (Ahlqvist et al., 2011). Furthermore, T2D rates
were observed to vary significantly between ethnic groups living within the same
environment where African Americans, Hispanic Americans and aboriginal North
Americans are at greater risk of T2D than American Caucasians (Carter et al., 1996;
Harris et al., 1998). Although linkage mapping studies first proposed chromosomal
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regions potentially housing T2D susceptibility genes, it was not until the high-resolution
GWAS approach was applied that T2D loci were discretely identified. The largest metaanalyses of T2D GWAS data have revealed as many as 58 T2D susceptibility loci which
strongly implicate the influence of β cell function at the centre of T2D susceptibility
(Voight et al., 2010; Zeggini et al., 2008). Despite these successes in expanding our
understanding of T2D-related pathways, common variation accounts for only ~10% of
T2D heritability. Clearly, further investigation is required in order to better understand
the nature of T2D risk and to account for the missing heritability.

1.4.3.3 Prevalence within First Nations communities
North American aboriginal populations are at increased T2D risk compared to the nonnative population. For example, T2D affects ~9% of the general Canadian population
versus 26% of Oji-Cree in Ontario, Canada (Lipscombe and Hux, 2007; Yu and Zinman,
2007). This increased T2D risk among the First Nations also extends to aboriginal
children as the incidence of childhood T2D in Manitoba first nations was nearly 8 times
higher compared to children across Canada in 2004-2006 (Amed et al., 2010).
Interestingly, Inuit populations in Canada and Alaska have shown low T2D prevalence,
however, high impaired glucose tolerance (IGT) prevalence has suggested that T2D may
eventually become problematic among Inuit populations (Pedersen, 2012). The enhanced
T2D risk among certain aboriginal Canadians identified epidemiologically is likely to be
explained by environmental or genetic components unique to these populations. Genetic
studies in aboriginal groups have been limited, however, a candidate gene study of
HNF1A in an Oji-Cree population identified the private p.G319S variant which was
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present in 40% of the population and increased T2D risk by 4-fold (Hegele et al., 1999).
The discovery of a common large-effect T2D variant was crucial in understanding the
propagation of T2D among the Oji-Cree and also underscored the importance of
investigating population-specific risk factors in understanding disease pathogenesis. As
genetic studies of aboriginal populations are relatively few, the investigation of putative
T2D-associated variation in isolated populations such as the Oji-Cree may help in
establishing T2D risk factors across ethnicities.

1.5 Summary

The concept of common and complex human disease has changed due to technological
and practical innovations in science and medicine. Although infectious diseases no longer
devastate Western society, the overall increase in life expectancy has led to the
emergence of complex diseases as the current leading causes of mortality. Common
complex disease etiology has been difficult to characterize since an intricate synergy
between environmental, epigenetic and genetic risk factors is suspected. Thus
considerable heterogeneity exists between any two patients diagnosed with CVD due to
the fact that, while their disease endpoints may be similar, the respective collection of
risk factors may be disparate. But while environmental factors may be modified, our
genetic make-up for the most part remains stable and so the hunt for robust genetic
determinants of complex disease susceptibility has been a major focus emerging from the
genomics era.
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The overall hypothesis of experiments performed in this thesis is that common
genetic variation contributes to the variance observed in common complex diseases and
traits and can be used to study complex disease susceptibility in multi-ethnic cohorts. We
sought to test this hypothesis through genetic analyses of three distinct complex diseaserelated phenotypes with the following objectives: 1) conduct a resequencing study of
LDLR in genetically isolated Inuit populations to identify novel variants associated with
LDL cholesterol and CVD risk; 2) conduct a targeted GWAS of common variation
previously linked with cardio-metabolic traits and AD in CIND patients in order to
evaluate the role of these pathways in CIND susceptibility; and 3) conduct a candidate
genotyping study of GWAS-identified T2D variants in Canadian aboriginal populations
in order to evaluate the applicability of established T2D loci in multi-ethnic populations.
Together, these studies exemplify different approaches to study the genetic basis of
complex disease and provide analytical workflows which may help in the design of future
studies on complex disease. As the genomics era is rapidly evolving with the introduction
of feasible whole genome sequencing, the concepts and analyses discussed in this thesis
are likely to remain fundamental to the future study of complex disease genetics.
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CHAPTER 2

THE PRIVATE, COMMON LDLR p.G116S VARIANT HAS A LARGE EFFECT
ON PLASMA LDL CHOLESTEROL IN CIRCUMPOLAR POPULATIONS

2.1 INTRODUCTION
Cardiovascular disease (CVD) represents a complex condition marked by progressive
atherosclerosis and inflammation leading to arterial occlusion and myocardial infarction
(Roy et al., 2009). Plasma low-density lipoprotein (LDL) concentration and, more
specifically, LDL cholesterol (LDL-C) represent major risk factors in determining CVD
risk. The lowering of LDL-C remains a primary goal in clinical CVD management
(Genest et al., 2009; Gotto and Moon, 2012). Over the past few decades, overall mortality
rates due to CVD have been on the decline particularly in North America, which is
believed to be due in large part to improved management of risk factors and improved
therapeutic interventions (Carroll et al., 2012; Gregg et al., 2005). Despite the overall
lower CVD risk, a countercurrent trend has emerged within global aboriginal and
indigenous communities where the increasing Westernization of diet and lifestyle has
correlated with increased prevalence of type 2 diabetes, obesity and ultimately CVD risk
(Stoner et al., 2012; Yu and Zinman, 2007).

Among the northerly aboriginal populations, Inuit descendants have presented a
unique case with respect to CVD risk as, historically, it was believed that Inuit
descendants were at lower CVD risk than non-native populations (Bjerregaard and
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Dyerberg, 1988; Middaugh, 1990; Young et al., 1993). It was a commonly held belief
that CVD was virtually non-existent within Inuit communities based on cardio-protective
effects of the traditional lifestyle and marine diet (Dewailly et al., 2001). Genetic factors
were also considered to account for the apparent cardiovascular protection observed
among the Inuit, however, a study on candidate CVD-associated variants among Inuit of
the Keewatin region of modern Nunavut showed that the Inuit carried a higher frequency
of certain CVD-associated variants compared to the non-native population (Hegele et al.,
1997). A closer analysis of CVD studies in Inuit populations suggested that the data used
to establish the concept of cardiovascular protection among the Inuit relative to nonnative populations was likely unfounded and that unreliable mortality statistics may have
helped perpetuate this concept when, in fact, rates of ischemic heart disease were similar
to non-native populations (Bjerregaard et al., 2003b). Preventive action against CVD
within Inuit communities has thus become increasingly paramount particularly as
progressive Westernization has gradually ushered in CVD risk factors such as smoking,
higher caloric intake and sedentary lifestyle that, while not immediately detrimental, may
potentially affect CVD prevalence for future generations (Bjerregaard et al., 1997;
Bjerregaard et al., 2003b; Chateau-Degat et al., 2010; Ebbesson et al., 2005; Howard et
al., 2010; Jernigan et al., 2010; Kellett et al., 2012).

As re-evaluation of Inuit health statistics show that the Inuit are not uniquely
protected from CVD risk (Schumacher et al., 2003), it is important to consider the unique
risk factors to which Inuit populations may be exposed. Recent Inuit health studies have
shown that a large percentage of adults live with high LDL-C (Jorgensen et al., 2008;
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Redwood et al., 2010). The prevalence of LDL-related diseases among the Inuit,
particularly familial hypercholesterolemia (FH, Online Mendelian Inheritance in Man
[OMIM] 143890) remains unreported and unexplored despite heterozygous FH (HeFH)
having one of the highest frequencies for a monogenic disease in North American and
European populations at a rate of 1:500 (Haase and Goldberg, 2012).

While LDL-C can be managed through diet and lifestyle, almost 80% of the
body’s cholesterol is derived endogenously which has placed greater emphasis on
understanding the biological mechanisms that modulate cholesterol homeostasis (Hegele,
2009). Genetic studies on FH identified deleterious mutations in the low-density
lipoprotein receptor (LDLR) gene as the cause of the observed hypercholesterolemia and
thus implicated LDLR as a major regulator of plasma LDL homeostasis (Goldstein and
Brown, 2009). To date, >1,700 hypercholesterolemia-associated variants in LDLR have
been reported suggesting that the LDLR locus is a hotspot for genetic variation. The role
of variation in LDLR in modulating LDL-C within Inuit populations has not been
investigated but given the prevalence of elevated LDL-C among select Inuit cohorts
(Bjerregaard et al., 2004; Ebbesson et al., 1996; Redwood et al., 2010), genetic variation
may be contributing to the variance in LDL-C observed in Inuit populations and may help
identify individuals at elevated CVD risk.

We therefore sought to investigate genetic variation at the LDLR locus within
Inuit descendants and test for association with lipid traits. Through Sanger sequencing of
LDLR and targeted genotyping, we report the discovery of two private, common LDLR
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variants in five Inuit populations from North America and Greenland. The first variant
encodes a glycine-to-serine substitution at the 116th amino acid (p.G116S), which was
previously reported in a Danish population (Damgaard et al., 2005), and the second
variant encodes a novel arginine-to-tryptophan substitution at the 730th amino acid
(p.R730W). Subsequent tests for association between these variants and lipid traits
strongly associate p.G116S with a large effect on LDL-C while p.R730W had a nonsignificant effect on LDL-C.

2.2 MATERIALS AND METHODS

2.2.1 Study populations
Participants of Inuit descent and aged >18 years were obtained from various arctic
regions within North America and Greenland (Figure 2.1, Table 2.1). Within Canada,
population-based samples were obtained from the “Qanuippitaa” health survey which
included 14 coastal communities in Nunavik, Quebec (n=450); the Keewatin Health
Assessment Study which surveyed residents of the Keewatin region in Nunavut (n=214)
(Moffatt et al., 1993); and the Inuvik region in the North West Territories (n=281).
Lastly, we included in our study a sample of Inuit living in Denmark and West Greenland
(n=1191) derived from a regional health survey (Bjerregaard et al., 1997) as well as
Yup’ik and Cup’ik Inuit from southwestern Alaska (n=1223) as part of the Center for
Alaska Native Health Research iniative (Boyer et al., 2007). Population-based samples of
the Oji-Cree (n=137) from Manitoulin Island, Ontario were also genotyped for G116S
and R730W.
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Figure 2.1 A map of select Inuit settlements across North America and Greenland.
A) Southwest Alaska is home to >20,000 Alaska Natives living in ~50 rural villages of
~500 inhabitants per village where Yup’ik and Cup’ik comprise the major Inuit
subpopulations. B) The Inuvik region of the Northwest Territories is home to ~3,200
Inuit descendants who represent ~35% of the population (Statistics Canada, 2006). C)
The former Keewatin region – now known as Kivalliq – in Nunavut is home to ~7,445
Inuit descendants who represent ~89% of the population (Moffatt et al., 1993). D) The
Nunavik territory of northern Québec lies north of the 55th parallel where the population
of ~11,000 is represented by ~91% Inuit. The entire population is spread across fourteen
coastal settlements (Counil et al., 2009). E) Greenland’s population of ~56,000 is
represented by ~90% Inuit where the majority of the population lives on the southwestern
coast (Bjerregaard et al., 2003a).
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n

Age

MAF
Female BMI
NonTC
LDL-C
HDL-C
apoB
TG
2
p.G116S
p.R730W
(%)
(kg/m )
HDL-C
1182 44±14
56
26±5
5.91±1.13 3.82±1.04 1.57±0.44 4.33±1.14 0.92±0.23 1.16±0.67 0.13
0.11
Greenland
210
37±16
54
27±4
5.00±1.03 3.09±0.92 1.45±0.41 3.55±1.01 0.98±0.26 1.03±0.57 0.02
0.17
Keewatin
281
45±16
67
30±7
5.05±0.99
2.91±0.89
1.37±0.42
3.68±1.03
0.91±0.25
1.74±1.27
0.05
0.13
Inuvik
429
37±14
56
27±6
4.99±0.99 2.79±0.86 1.63±0.43 3.33±1.02 0.96±0.24 1.23±0.72 0.09
0.13
Nunavik
1222 38±16
53
28±6
5.20±1.15 3.20±0.98 1.64±0.44 3.61±1.08
n.d.
0.94±0.56 0.10
0.16
Alaska
3324 40±16
56
27±6
5.40±1.16 3.30±1.05 1.58±0.44 3.83±1.15 0.93±0.24 1.13±0.74 0.10
0.14
Combined
All demographics are reported ± standard deviation. Lipid-related traits are all reported in mmol/L except apoB which is in g/L. BMI, body mass
index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; MAF, minor allele frequency; n.d., no data; TC,
total cholesterol concentration; TG, triglyceride concentration.

Table 2.1. Demographics and LDLR variant frequencies for select circumpolar populations.
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Generally, participants were asked to fast either for 12 hours or overnight prior to
blood sample collection. Plasma lipid concentrations were determined using varying
methods across the different Inuit population studies. Carotid intima-media thickness
(IMT)

measurements

were

obtained

using

established

ultrasound

protocols.

Measurements were calculated for 12 1-cm segments which included the near and far
walls of the common carotid artery and bifurcation of the common carotid artery. For
analysis with LDLR variant genotypes, mean IMT included an average of all 12
segments; mean common carotid IMT (C-IMT) included the average of 4 segments
exclusively covering the common carotid artery.

2.2.2 Study design
The LDLR promoter region and exons were Sanger sequenced within a subset of
Greenland Inuit participants (n=10) with LDL-C concentrations >95th percentile (~6.00
mmol/L). The p.G116S and p.R730W variants were identified in exons 4 and 15 of LDLR
respectively (Figure 2.2). Study participants from four independent Inuit populations
were subsequently genotyped for the two variants (Table 2.2). Genotypes were first used
to test for association with quantitative lipid traits including plasma total cholesterol
(TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), non-HDL-C and triglyceride
concentration (TG) within each Inuit population as well as apolipoprotein B (APOB)
concentration where available. The four Inuit populations were then combined and reassessed for association with lipid traits. The LDLR variants were genotyped using either
TaqMan SNP genotyping assays (Applied Biosystems; Foster City CA) or direct Sanger
sequencing. Apolipoprotein E (APOE) isoforms were inferred based on haplotypes using
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Figure 2.2 Structural organization of the human LDL receptor protein and the
relative positions of the p.G116S and p.R730W variants. The 839-amino acid mature
protein is shown here with corresponding exon and domain annotations. Modified from
Hobbs et al (1990).
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p.G116S
Exon 4

p.R730W
Exon 15

Chr19:11,215,991

Chr19:11,233,960

c. 2251C>T

c.409G>A

Nucleotide
substitution

PMUT
SIFT
PolyPhen
MutPred

PMUT
SIFT
PolyPhen
MutPred

in silico
algorithm

n.d.
0.04
0.951
n.d.

n.d.
0.01
0.999
n.d.

Score

Pathological
Damaging
Possibly damaging
0.51 probability of deleterious mutation

Neutral
Damaging
Probably damaging
0.81 probability of deleterious mutation

Prediction

Amino acid positions for mutations refer to the mature protein. Abbreviations as in Table 2.1.

Variant

Position

Table 2.2. In silico analyses of p.G116S and p.R730W on LDLR function.
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rs429358 and rs7412 which encode amino acid substitutions p.C112R and p.C158R
respectively (Fullerton et al., 2000). APOE genotypes for SNPs rs429358 and rs7412
were also determined using pre-designed TaqMan assays.

2.2.3 Statistical analysis
Study cohort demographics were evaluated within each Inuit subpopulation using t-tests
or ANOVA for continuous variables using SAS v9.2 (Cary, NC); statistical significance
was defined as P<0.05. We tested for association between LDLR variant genotypes and
lipid-related traits using multivariate linear regression within each Inuit subpopulation
using an additive genetic model adjusted for age, sex and BMI as previously reported
(Lanktree et al., 2009). Multi-variate regression in the combined Inuit cohort, comprising
all 5 Inuit population samples, was additionally adjusted for geographic location.
Regression analyses between LDLR genotypes and plasma lipid traits, pairwise linkage
disequilibrium and haplotype phase were investigated using the PLINK bioinformatics
toolkit

(http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al., 2007).

2.2.4 Bioinformatic analysis
Variant effects on LDLR function were predicted using PMUT (Ferrer-Costa et al.,
2005), Polyphen (Adzhubei et al., 2010), MutPred (Li et al., 2009) and SIFT (Ng and
Henikoff, 2001) variant modeling algorithms. Algorithm scores for p.G116S and
p.R730W were included where available. Evolutionary conservation was investigated
across species at amino acid positions in the vicinity of p.G116S and p.R730W using the
BLAST alignment tool which aligns homologous regions from a range of available
species (Kent, 2002). Reported FH mutations in LDLR were referenced from the Human
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Gene Mutation Database (Stenson et al., 2009). The 1000 Genomes Project and the
Exome Variant Server (http://evs.gs.washington.edu/EVS/) variant databases were also
referenced for previous reports of p.G116 or p.R730W (Abecasis et al., 2012). The 1000
Genomes Project reports variants with frequencies >1% from 1,092 sequenced genomes
from multiple ethnicities. The Exome Variant Server reports variants from the National
Heart, Lung, and Blood Institute (NHLBI) GO Exome Sequencing project which
maintains exome sequencing data on more than 200,000 individuals.

2.3 RESULTS

2.3.1 Study subjects
Demographic data from five Inuit cohorts are shown in Table 2.1. Overall, demographic
attributes between Inuit cohorts were comparable with each sample population
represented by average ages >35 years and female participants representing the majority
or >50% of the sample. Average plasma lipid traits were also consistent between Inuit
populations.

2.3.2 LDLR variant discovery and frequencies
First, p.G116S and p.R730W were detected following direct Sanger sequencing of LDLR
exons within a subgroup of the Greenland cohort with LDL-C >6.00 mmol/L (n=10). The
Greenland population sample was selected for Sanger sequencing as it was the only
sample available at the initiation of this study. We then sought to establish p.G116S and
p.R730W variant frequencies within the five additional Inuit cohorts and a combined
cohort incorporating all five Inuit sample populations. Both variants were observed with
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common frequencies >1% within each Inuit population (Table 2.1). The p.G116S variant
ranged in frequency from 2% in the Keewatin cohort to 13% in the Greenland cohort
with an overall frequency of 10% when all cohorts were combined. The p.R730W variant
was consistently observed at a high frequency ranging from 11% in the Greenland cohort
to 17% in the Keewatin cohort with a combined frequency of 14%. The p.G116S and
p.R730W were both absent from an indigenous Canadian First Nations population
sample. Furthermore, neither G116S nor R730W had been reported by the 1000 Genomes
Project or the NHLBI GO Exome Sequencing Project.

2.3.3 In silico analyses suggest p.G116S and p.R730W introduce deleterious effects
on LDLR function
As the functional domains of LDLR have been well-characterized (Figure 2.2), we
determined that the p.G116S variant in exon 4 was localized within the ligand binding
domain. Out of the 1,763 hypercholesterolemia mutations identified in LDLR to date, 183
are found within exon 4 suggesting that this locus is a hot-spot for FH-related mutation
(Stenson et al., 2009). Using BLAST sequence alignment, we observed that glycine at the
116th amino acid in LDLR was conserved across 10 additional orthologous LDLR
homologs further suggesting that mutations at this amino acid are not well tolerated
(Figure 2.3). A glycine-to-serine substitution introduces a polar residue of higher
molecular weight and greater hydrophilicity which may impact upon local folding
particularly as exon 4 encodes 3 of 7 cystein-rich repeats found within the ligand binding
domain with each repeat modulating ligand binding (Hobbs et al., 1990). Accordingly,

53

Figure 2.3 Amino acid conservation in the vicinity of p.G116S and p.R730W.
Multiple amino acid residue sequence alignments from divergent species show
conservation at amino acids 116 and 730 in LDLR (highlighted in red). Amino acid
residues conserved between homologs are highlighted in blue and indicate local
conservation.
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we investigated the predicted effects of p.G116S on LDLR function using four
independent mutation prediction algorithms (Table 2.2). Three algorithms predicted
damaging effects of G116S on LDLR function while the PMUT algorithm predicted a
neutral effect. Another variant at p.G116, a glycine-to-cysteine substitution (p.G116C),
was previously reported in Polish FH patient and was predicted to have a deleterious
effect on LDLR function (Chmara et al., 2010). The report of p.G116C provides
additional support that G116 is an important residue in LDLR function.

Similar bioinformatic analyses were performed using p.R730W. p.R730W is
located in exon 15 which encodes an attachment site for O-linked carbohydrate chains
and has no clear functional role in LDLR activity (Hobbs et al., 1990). In comparison to
exon 4, only 19 hypercholesterolemia mutations have been reported in exon 15 (Stenson
et al., 2009). Sequence conservation in the vicinity of p.R730W is also comparatively less
strict suggesting mutations within this exon may be more tolerable than in exon 4 (Figure
2.3). An arginine-to-tryptophan substitution introduces a larger molecular weight residue
with a shift from polar to neutral charge and decreased hydrophilicity; however it is not
clear how this substitution may affect the binding of O-linked sugars at this domain or
impact LDLR function. Mutation prediction algorithms all predicted deleterious effects
on LDLR function for p.R730W. However, milder effects were predicted relative to
p.G116S as MutPred predicted a lower probability of a deleterious effect compared to
p.G116S and Polyphen reported p.R730W as “Possibly damaging” as opposed to
“Probably damaging”. At the p.R730W residue, an arginine-to-glutamine (p.R730Q)
mutation was reported in a Dutch FH cohort and was predicted as “Tolerated” and “Low
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Risk” (Fouchier et al., 2005). Although p.R730Q was identified in a cohort of FH
patients, the frequency of the mutation is not known nor is it clear whether carriers of
p.R730Q may have carried additional FH-causing mutations. Thus the importance of
residue arginine at amino acid 730 does not appear as robust as glycine at amino acid 116
in maintaining LDLR function.

2.3.4 Mean lipid traits differ based on p.G116S or p.R730W genotype
As LDLR is a major regulator of plasma cholesterol homeostasis, we tested for
association between both p.G116S or p.R730W carrier status and plasma lipid traits.
Within each population sample, carriers of p.G116S had significantly higher average TC
and LDL-C concentrations compared to non-carriers by ~0.7 mmol/L for p.G116S
heterozygotes in the combined Inuit cohort (Table 2.3A); mean TC and LDL-C among
p.G116S homozygotes for serine at amino acid 116 was nearly 1 mmol/L higher than
homozygotes for glycine at amino acid 116. Mean apoB and non-HDL-C concentrations
were also consistently higher among p.G116S carriers compared to homozygotes for
glycine at amino acid 116 (Table 2.3A, 2.3B). Conversely, p.R730W carrier status was
not robustly linked with any lipid trait within the individual Inuit cohorts. However,
examination of the combined Inuit cohort revealed a significantly lower mean LDL-C
and non-HDL-C concentrations as well as higher HDL-C in p.R730W carriers versus
non-carriers (Table 2.3A, 2.3B).

6.40±1.07
6.02±0.97*
5.58±1.07
5.38±1.13
5.62±1.32
5.94±1.24

5.74±1.09
4.93±0.97
5.00±0.98
4.90±0.94
5.16±1.10
5.29±1.11

CT
5.90±1.17
4.87±1.00
4.86±0.97
4.93±0.90
5.29±1.14
5.37±0.17

CC

5.91±1.12
4.98±1.00
5.10±1.01
4.94±0.96
5.23±1.16
5.43±1.17

TC

GA

GG

6.1±1.09
5.18±0.91
5.15±0.81
5.52±0.93
5.18±1.08
5.47±1.07

TT

6.70±1.32**
n.d.
5.05±0.11*
6.27±0.58**
5.57±0.96**
6.20±1.25**

AA

3.83±1.03
3.08±0.90
2.97±0.90
2.80±0.84
3.21±1.00
3.37±1.06

CC

3.63±0.99
3.02±0.87
2.88±0.86
2.72±0.82
3.12±0.91
3.22±0.98

GG

3.78±1.08
2.96±0.92
2.78±0.86
2.71±0.85
3.22±0.94
3.28±1.04

CT

LDL-C

4.34±0.98
4.11±0.90*
3.43±1.03
3.11±0.97
3.58±1.17
3.88±1.14

GA

LDL-C

3.73±0.72
3.19±0.76
2.98±0.40
3.14±1.04
3.19±0.85
3.20±0.82*

TT

4.70±1.12**
n.d.
3.27±0.20*
3.90±0.77**
3.61±0.96**
4.21±1.14**

AA

GA

0.92±0.22
0.97±0.25
0.92±0.26
0.95±0.23
n.d.
0.93±0.23

CC

0.91±0.24
0.95±0.26
0.87±0.24
0.93±0.24
n.d.
0.91±0.24

CT

APOB

0.89±0.22 1.02±0.24
0.95±0.24 1.36±0.12**
0.90±0.25 1.03±0.25
0.94±0.24 1.02±0.24
n.d.
n.d.
0.90±0.23 1.03±0.24

GG

APOB

* indicates P<0.05 and **indicates P<0.0001 using ANOVA adjusted for age, sex and BMI. Abbreviations as in Table 2.1.

R730W
genotype
Greenland
Keewatin
Inuvik
Nunavik
Alaska
Combined

G116S
genotype
Greenland
Keewatin
Inuvik
Nunavik
Alaska
Combined

TC

Table 2.3A Mean lipid traits based on p.G116S or p.R730W genotype.

0.95±0.31
0.98±0.22
0.91±0.18
1.04±0.28
n.d.
0.97±0.27

TT

1.10±0.20**
n.d.
0.95±0.04*
1.24±0.19*
n.d.
1.11±0.20**

AA
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1.54±0.40
1.51±0.47
1.39±0.40
1.71±0.47
1.64±0.45
1.59±0.43

1.58±0.45
1.44±0.41
1.35±0.41
1.61±0.42
1.64±0.44
1.57±0.44

CT
1.56±0.45
1.46±0.37
1.40±0.46
1.67±0.42
1.68±0.47
1.61±0.46

CC

1.57±0.44
1.43±0.41
1.36±0.41
1.61±0.43
1.62±0.43
1.56±0.44

HDL-C

GA

GG

1.65±0.46
1.65±0.53
1.42±0.35
1.83±0.38
1.70±0.42
1.68±0.45*

TT

1.58±0.48
n.d.
1.17±0.15
1.92±0.77
1.56±0.46
1.58±0.49

AA

4.33±1.13
3.57±0.97
3.73±1.05
3.31±0.98
3.62±1.10
3.86±1.15

CC

4.16±1.09
3.48±0.94
3.65±1.03
3.25±0.99
3.52±1.03
3.71±1.09

GG

4.34±1.20
3.41±1.02
3.48±0.99
3.23±0.99
3.61±1.05
3.76±0.16

CT

Non-HDL-C

4.84±1.12
4.51±0.89*
4.20±1.03
3.68±1.05
3.98±1.26
4.35±1.24

GA

Non-HDL-C

4.45±1.17
3.53±0.80
3.67±0.76
3.69±1.17
3.48±1.06
3.80±1.10*

TT

5.13±1.18**
n.d.
3.88±0.04*
4.35±0.90*
4.01±1.01**
4.62±1.20**

AA

1.14±0.64
1.04±0.54
1.80±1.38
1.56±0.63
0.95±0.58
1.12±0.76

CC

1.18±0.68
1.01±0.55
1.74±1.32
1.24±0.75
0.96±0.58
1.13±0.75

GG

1.24±0.75
0.98±0.59
1.54±0.78
1.21±0.72
0.95±0.52
1.11±0.67

CT

TG

1.16±0.66
0.87±0.39
1.86±0.81
1.25±0.56
0.90±0.47
1.09±0.62

GA

TG

* indicates P<0.05 and **indicates P<0.0001 using ANOVA adjusted for age, sex and BMI. Abbreviations as in Table 2.1.

R730W
genotype
Greenland
Keewatin
Inuvik
Nunavik
Alaska
Combined

G116S
genotype
Greenland
Keewatin
Inuvik
Nunavik
Alaska
Combined

HDL-C

Table 2.3B Mean lipid traits based on p.G116S or p.R730W genotype.

1.35±0.95
0.74±0.28
1.70±0.72
1.20±0.44
1.00±0.54
1.11±0.68

TT

0.96±0.30
n.d.
1.34±0.54
0.99±0.32
0.94±0.47
0.97±0.38

AA
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2.3.5 p.G116S is associated with LDL-C concentration
As LDL-C appeared to underlie the differences in cholesterol concentrations in S116 and
W730 carriers, we next sought to investigate the effects of G116S and R730W on LDL-C
using genetic models adjusted for age, sex and BMI. Frequency distributions based on
p.G116S within the combined Inuit cohort suggested an additive effect on LDL-C
concentration. Mean LDL-C concentrations were significantly different between
homozygotes for glycine at amino acid 116 and p.G116S heterozygotes (P=2.0x10-34,
Figure 2.4A). Furthermore, the difference in mean LDL-C concentrations between
p.G116S heterozygotes and homozygotes approached significance (P=0.058, Figure
2.4A). p.R730W genotype did not follow a distinct genetic model as the mean LDL-C for
homozygotes for arginine at amino acid 730 differed significantly from the mean LDL-C
concentration of p.R730W heterozygotes (P=0.031); however, mean LDL-C did not
differ significantly between p.R730W heterozygotes and homozygotes for tryptophan at
amino acid 730 (P=0.77, Figure 2.4B). Plotting LDL-C concentrations for all participants
based on p.G116S or p.R730W genotype revealed linear trends between LDL-C and each
additional copy of either the p.G116S or p.R730W variant (Figure 2.4C, 2.4D). We used
multi-variate linear regression to test whether the observed variant-LDL-C trends also fit
linear models. Within each Inuit cohort, p.G116S was associated with increased LDL-C.
In a combined cohort of all Inuit population samples, each copy of the S116 variant was
associated with a ~0.54 mmol/L increase in LDL-C (P=5.6x10-49, Table 2.4). W730 was
non-significantly linked with lower LDL-C within each Inuit cohort and was linked with
an overall lowering effect on LDL-C by ~0.05 mmol/L (P=0.13, Table 2.4). p.G116S and
p.R730W variants were not in strong linkage disequilibrium (r2=0.017) and were not
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Figure 2.4 LDLR variants and trends with LDL-C in a combined Inuit cohort. Inuit
participants were separated based on p.G116S or p.R730W genotype and LDL-C
concentration. A) Frequency distribution of Inuit participants based on p.G116S carrier
status and LDL-C concentration. Mean LDL-C concentrations between non-carriers (GG,
n=2585), heterozygotes (GA, n=559) and homozygotes (AA, n=53) were compared using
t-tests with P-values indicated. B) Frequency distributions were similarly constructed for
p.R730W non-carriers (CC, n=2408), heterozygotes (CT, n=717) and homozygotes (TT,
n=72) and were also compared using t-tests. C) Distribution of LDL-C concentrations
based on p.G116S genotype per study participant following an additive genetic model
with a calculated line of best fit. D) Distribution of LDL-C concentrations per participant
were similarly plotted for p.R730W genotype.
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predicted to be in phase within the same haplotype. We therefore could not investigate
the effect of a haplotype containing both p.G116S and p.R730W on any lipid traits.

2.3.6 p.G116S effect on LDL-C is greater than APOE E4 and common LDL-C
GWAS variants
The p.G116S variant represents a unique combination of both high variant frequency
(~10%, Table 2.1) and large effect size (~0.54 mmol/L per p.G116S allele, Table 2.4).
APOE E4 isoform has similarly been established as a high-frequency variant robustly
associated with LDL-C (Khan et al., 2013; Ward et al., 2009). We therefore tested for
association between APOE E4 and LDL-C in the Inuit population samples in order to
compare effect sizes between the novel p.G116S variant and the established APOE E4
isoform. APOE E4 frequencies were comparable across the four Inuit populations in
which APOE isoform status was available and ranged from 21% to 27% (Table 2.5).
Using multi-variate linear regression to estimate the per-allele effect size on LDL-C, we
identified a robust association between APOE E4 and LDL-C exclusively within the
Greenland population sample (0.22 mmol/L, P=8.2x10-6; Table 2.5); in a combined
cohort of all Inuit population samples the effect was diminished but remained significant
(0.15 mmol/L, P=1.8x10-5; Table 2.5). In comparison, the p.G116S-associated effect on
LDL-C was almost 4-fold greater than APOE E4 in combined Inuit cohorts.

GWAS have comprehensively identified robust associations between common
variants and LDL-C (Teslovich et al., 2010). In order to further give context to the
p.G116S-associated frequency and effect on LDL-C, we compared p.G116S to the most
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Table 2.4 Associations between two LDLR variants and LDL-C.
Variant

Population

β (mmol/L)

SE

P-value

p.G116S

Greenland
Keewatin
Inuvik
Nunavik
Alaska
Combined

0.64
1.02
0.52
0.40
0.41
0.54

0.05
0.27
0.16
0.09
0.06
0.04

1.8x10-30
1.7x10-4
0.0011
3.7x10-5
9.4x10-12
5.6x10-49

p.R730W

Greenland
Keewatin
Inuvik
Nunavik
Alaska
Combined

-0.11
-0.003
-0.13
-0.05
-0.01
-0.05

0.06
0.09
0.11
0.08
0.05
0.03

0.077
0.97
0.24
0.52
0.85
0.13

Effect sizes and P-values are based on the minor alleles p.G116S or
p.R730W. SE, standard error. Greenland (n=1162) Keewatin (n=204)
Inuvik (n=253) Nunavik (n=389) Alaska (n=1113) Combined (n=3121).
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Table 2.5 APOE E4 effect on LDL-C in select Inuit populations.
Population
Greenland
Keewatin
Inuvik
Nunavik
Combined

E4
frequency
0.22
0.21
0.23
0.27
0.23

β
(mmol/L)
0.22
0.06
0.006
0.09
0.15

SE

P-value

0.049
0.10
0.10
0.06
0.03

8.2x10-6
0.56
0.95
0.17
1.8x10-5

ApoE E4 effect sizes were calculated in comparison to E3 carriers
using linear regression adjusted for age, sex and BMI in Keewatin
(n=200), Greenland (n=1096), Inuvik (n=212), Nunavik (n=383),
and a combined cohort (n=1891). ApoE E4 frequencies were
calculated from larger populations including ApoE E2, E3 and E4
carriers.
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significant LDL-C GWAS variants which we listed in Table 2.6. Together, the strongest
association signal at SORT1 as well as associations at candidate LDL-C loci such as
LDLR, APOB and PCSK9 corresponded to effect sizes ranging from 0.05 mmol/L to 0.18
mmol/L which are overshadowed by the ~0.54 mmol/L per-allele effect size we ascribed
to p.G116S.

2.3.7 Mean IMT is not linked with p.G116S or p.R730W genotype
Mean IMT is an established marker of atherosclerosis and is correlated with plasma
LDL-C concentrations (Negi and Nambi, 2012; Sun et al., 2000). As we identified
associations between p.G116S and p.R730W, and LDL-C, we sought to test whether
either LDLR variant genotype was also linked with changes in IMT. Using available IMT
measurements from the Inuvik and Nunavik population samples, we compared mean IMT
measurements between the LDLR variant genotypes and observed no significant
difference suggesting no clear effect on IMT based on LDLR variant genotype (Table
2.7).

2.4 DISCUSSION

The major finding of our study is the discovery of two common LDLR variants, p.G116S
and p.R730W, which are private among Inuit populations. Furthermore, we showed that
the p.G116S variant was robustly associated with a large increase in plasma LDL-C while
p.R730W showed a modest non-significant LDL-C-lowering effect. The p.G116S variant
was also unique due to the high frequency of the variant coupled with a large effect size
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Table 2.6 The most significant LDL-C-associated common
variants.
β
P-value
(mmol/L)
1
SORT1
rs629301
0.15
1x10-170
19
APOE
rs4420638
0.18
9x10-147
19
LDLR
rs6511720
0.18
4x10-117
2
APOB
rs1367117
0.10
4x10-114
2
ABCG5/8
rs4299376
0.07
2x10-47
1
PCSK9
rs2479409
0.05
2x10-28
Effect sizes and P-values were reported by Teslovich et al.
(Teslovich et al., 2010)
CHR

Locus

SNP
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Table 2.7 IMT measurements based on p.G116S and p.R730W genotypes.
C-IMT
p.G116S
genotype
Inuvik
Nunavik

p.R730W
genotype
Inuvik
Nunavik

Average IMT

GG

GA

AA

GG

GA

AA

0.73±0.17
(n=54)
0.78±0.16
(n=83)

0.73±0.20
(n=7)
0.74±0.13
(n=20)

n.d.

0.56±0.16
(n=41)
0.83±0.19
(n=5)

0.50±0.21
(n=6)
0.77±0.20
(n=4)

n.d.

CC

CT

TT

CC

CT

TT

0.73±0.15
(n=44)
0.77±0.16
(n=74)

0.74±0.19
(n=15)
0.75±0.16
(n=24)

0.59±0.03
(n=2)
0.86±0.14
(n=5)

0.54±0.17
(n=34)
0.84±0.19
(n=7)

0.59±0.15
(n=12)
0.68±0.01
(n=2)

0.57±0.00
(n=1)
n.d.

n.d.

n.d.

Statistical significance was tested using ANOVA. Inuvik participants with C-IMT (n=61)
and average IMT (n=47), and Nunavik participants with C-IMT (n=103) and average IMT
(n=9) were included for analysis. Abbreviations as in Table 2.1; C-IMT, common carotid
intima-media thickness. All units are expressed in mm.
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on LDL-C. Our study has thus proposed a genetic CVD risk factor exclusive to Inuit
descendants with potential clinical utility.

Our discovery of the association between the p.G116S variant and LDL-C
concentration is of particular interest from a public health perspective as circumpolar
Inuit communities are currently facing increased risk of CVD compared to non-Inuit
populations. Early Inuit population studies propagated the concept of low CVD mortality
among Inuit communities based on marine diet and a possible genetic component,
however, subsequent analysis have largely dispelled this myth (Bjerregaard et al., 2003b).
As introduced earlier, subsequent studies on CVD in Inuit communities have suggested
greater CVD risk within Inuit communities compared to non-Inuit populations as
Westernization influences the lifestyles of the younger generation. Given that every 1
mmol/L increase in LDL-C corresponds to a ~21% increase in CVD and ~16% increase
in all-cause mortality, the 0.54 mmol/L increase in LDL-C per p.G116S allele could
potentially lead to ~10% increases in CVD and all-cause mortality respectively (Gould et
al., 2007).

In addition to the implications on LDL metabolism, the p.G116S and p.R730W
variants are distinct based on the high frequencies observed within our study cohorts.
Within the context of the common disease-common variant hypothesis (CDCV), which
proposed that a limited number of common variants underlies common complex disease
etiology (Lander, 1996), the large effect size associated with p.G116S was unexpected
given the high minor allele frequency (Figure 2.5). The APOE E4 isoform represents an
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Figure 2.5 The common disease-common variant hypothesis in relation to the G116S
variant. LDL-associated variants have adhered to the CDCV hypothesis-predicted trend
where A) low-frequency mutations, as observed in FH, contribute large effects on LDL
concentrations whereas B) common variants, as identified through GWAS on LDL, are
typically associated with small effects on plasma LDL. The novel C) G116S variant is
unique as it represents a common variant with a considerable effect on plasma LDL.
Modified from Manolio et al. (2009).
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established high-frequency variant with a robust association with higher LDL-C.
Compared to E3 homozygotes, each copy of E4 was associated with a 0.16 mmol/L
increase in LDL-C (Khan et al., 2013). We replicated a similar effect size in a combined
Inuit cohort (0.15 mmol/L per copy of E4; Table 2.5); however, it was clear that S116
had a considerably greater impact on LDL-C. As the top LDL-C SNPs from across the
genome reflected similar effect sizes as APOE E4, which ranged from 0.05 mmol/L to
0.18 mmol/L (Table 2.6), it is clear that the combination of the G116S frequency and
effect size is anomalous. Despite the large effect size of p.G116S, it is interesting that
p.G116S homozygotes do not appear to express the dramatic phenotypes that are
observed with patients homozygous for FH-causing mutations.

The LDLR amino acid positions of 116 and 730 provide insight on potential
effects on LDLR function (Figure 2.2). Amino acid 116 lies within exon 4 of LDLR
which encodes the ligand binding domain. As this domain is important for the binding
and internalization of apoB-containing lipoprotein particles, p.G116S can potentially
perturb binding affinity and thus LDLR activity; this hypothesis was supported by
predictions of potentially damaging effect by two in silico algorithms. Exon 15, which
contains amino acid 730, is enriched for serine and threonine residues which facilitate
attachment of O-linked carbohydrate chains; however, the absence of exon 15 has not
been associated with any significant functional consequence in vitro (Hobbs et al., 1990).
This observation runs contrary to both our in silico analysis which anticipated potentially
damaging effects on LDLR function as well as the potential gain-of-function effect that
we observed with p.R730W in modest lowering of LDL-C. In order to better understand
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the effects of either variant on LDLR function, direct biochemical analyses measuring
LDLR expression and activity must be implemented.

Our findings also provide further support for the concept of a unique genomic
architecture within the Inuit. It remains a question as to how p.G116S and p.R730W
reached high frequency across the circumpolar Inuit populations; however, this
phenomenon is likely explained by the founder effect. Various sources of evidence have
supported the original founding human populations in the Americas by Asians (Hey,
2005). It is possible that carriers of p.G116S and p.R730W were among the small founder
populations that migrated eastward from Alaska towards Greenland. As founder
populations in geographic isolation are able to expand in numbers, limited genetic
heterogeneity facilitates the inflation of allele frequencies that may have been rare in a
larger non-related population. Similar founder effects have historically been observed,
particularly in the case of FH frequency where founder populations such as the
Quebecois in Canada and Dutch immigrants to South Africa report remarkably high FH
frequencies due to the propagation of founder mutations (Liyanage et al., 2011). Through
mechanisms such as the founder effect, it is therefore possible for variants to gain high
frequency despite potentially negative effects on health and mortality particularly as
HeFH mutations are less penetrant and do not increase selective pressure before
reproductive age.

In addition to the p.G116S and p.R730W variants described here, the p.P479L
substitution in the carnitine palmitoyltransferase IA gene (CPT1A) has been identified as
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a private variant among Inuit and Canadian First Nations populations where the p.P479L
variant was associated with hypoketosis and hypoglycemia (Brown et al., 2001; Lemas et
al., 2012; Rajakumar et al., 2009). Together, the identification of these high-frequency
variants with large effect sizes suggests that Inuit descendants may possess a unique
genetic architecture with effects on cardio-metabolic traits that are not fully identified nor
understood. With the increasing viability of whole genome and exome sequencing, it will
be possible to perform a comprehensive scan for genetic variation within the Inuit.
Additional evidence of unique variation relating to cardiovascular health will further
support the concept that Inuit communities may be exposed to unique CVD risk which
may require unique guidelines for more efficient and targeted CVD prevention and
management.

A potential limitation within this study pertains to our limited information on
participant relatedness. As Inuit communities are generally isolated with low net
population migration, it is expected that genetic heterogeneity is lower compared to the
level that may be observed in the general population. For the purpose of genetic
association, limited genetic heterogeneity is considered advantageous as this limits the
pool of variants present within the population and thus limits the probability of false
positive association. Conversely, closely related individuals may have a similar lipid
profile due to shared environmental or additional genetic factors which may contribute to
spurious associations. Future studies will require detailed family structure and relatedness
data in order to adjust for the effects of relatedness on observed associations.
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Furthermore, our claim that p.G116S is private to Inuit descendants was
questioned by the previous report of p.G116S in a Danish FH cohort (Damgaard et al.,
2005). As Greenland continues to share a history of migration and sociocultural
interaction

with

Denmark,

it

is

possible that

a

patient

or

patients

with

hypercholesterolemia as well as Inuit ancestry were included in the Danish FH cohort.
However, this remains speculative as records on patient ethnicity were not published.

Our study was also limited to reporting on the discovery of p.G116S and
p.R730W, the associations with plasma LDL-C concentration and in silico prediction
analysis. We sought to test for association with IMT; an established marker of CVD.
However, no robust association was detected between IMT and LDLR variant genotype.
While this experiment suggested that the 0.54 mmol/L increase in LDL-C associated with
p.G116S does not correlate with thickening of the carotid artery walls, a major caveat to
this interpretation was the limited sample size as well as variability in the application of
IMT measurement methodology. Functional studies of the potential effects of these
variants on LDLR bioavailability remain to be performed but are crucial in elucidating
the mechanism underlying the robust association between p.G116S and LDL-C
concentration and establishing a causal effect between p.G116S and elevated LDL-C.
Going forward, we propose to first assess LDLR expression based on G116S and R730W
genotype within in vitro Chinese hamster ovary cell-based models and immunoblotting
followed by assessment of LDLR activity via fluorescently-labelled LDL uptake assays.
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In summary, we have discovered the presence of two common LDLR variants that
are exclusive among Inuit descendants from five distinct communities within Alaska,
Canada and Greenland. We have further identified a strong association between p.G116S
and plasma LDL-C concentration which has implicated p.G116S in CVD risk. The
clinical utility of these findings in assessing CVD risk prediction is not presently clear as
robust statistics on Inuit CVD mortality are not currently available and that Inuit
communities continue to undergo progressive westernization which may affect CVD risk
and prevalence over the coming decades. Additional studies involving biological
assessment of p.G116S and p.R730W on LDLR function as well as broader investigation
in outstanding circumpolar Inuit populations will provide a greater understanding of the
role played by these variants in LDL metabolism and overall CVD susceptibility.
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CHAPTER 3

GENETIC DETERMINANTS OF “COGNITIVE IMPAIRMENT, NO
DEMENTIA”

The work in this chapter originates from material in the following publication: Dubé,
J.B., Johansen, C.T., Robinson, J.F., Lindsay, J., Hachinski, V., and Hegele, R.A. (2013).
Genetic determinants of "cognitive impairment, no dementia". J Alzheimers Dis 33, 831840.

3.1 INTRODUCTION
Dementia is primarily a disease of the elderly defined by insidious cognitive decline that
impairs social and occupational functioning (American Psychiatric Association. Task
Force on DSM-IV., 1994; Burns and Iliffe, 2009; Feldman et al., 2008; Geldmacher and
Whitehouse, 1996). An early phenotype of cognitive decline that affects ~10-20% of
elderly populations (Di Carlo et al., 2007; Graham et al., 1997) is called “cognitive
impairment, no dementia” (CIND). CIND is defined broadly by subtle deficiencies in
memory or executive functioning that do not fit the definition of dementia but are also
abnormal (Chertkow et al., 2008; Tuokko et al., 2001). These findings are commonly
associated with increased susceptibility to more severe, later stages of dementia (Tuokko
et al., 2003) thus a thorough understanding of the pathogenesis of CIND could lead to
improved methods for identifying at-risk patients.

82

The late stages of dementia are most commonly associated with AD- and vascular
dementia (VaD)-related mechanisms of pathogenesis. The prevailing models of AD
pathogenesis have implicated perturbations in lipid metabolism, intracellular trafficking
and inflammatory pathways that are associated with hallmarks such as β-amyloid (Aβ)
plaque deposition and neurofibrillary tangles (NFTs) (Holtzman et al., 2012; Huang and
Mucke, 2012). The mechanisms underlying VaD are defined by progressive degeneration
or occlusion of the cerebrovasculature that is believed to contribute to a
microenvironment of hypoxia and inflammation in the brain (Ballard et al., 2004;
Cechetto et al., 2008; Gorelick et al., 2011; Kalaria, 2000; Wolf, 2012). Positive
association between AD or cardio-metabolic traits with CIND susceptibility may
implicate the effects of established late-stage degenerative mechanisms at an earlier stage
of cognitive decline.

Genetic variation has been associated with both AD (Hollingworth et al., 2011;
Naj et al., 2011) and the cardiovascular traits associated with vascular disease (Hegele,
2009; Teslovich et al., 2010), however no studies have tested for association between
these variants and CIND susceptibility. Genome-wide association studies (GWAS)
(Hirschhorn and Daly, 2005) are a method of testing for association between genetic
variation and a heritable trait that has successfully identified novel genes involved in
vascular health such as blood lipid traits (Hegele, 2009; Teslovich et al., 2010) or disease
phenotypes such as Alzheimer-related dementia (Hollingworth et al., 2011; Naj et al.,
2011). A GWAS-based approach applied to CIND could reveal whether genes implicated
in VaD and AD susceptibility are also associated with CIND. Here, we conduct a GWAS
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to determine whether genetic variation previously associated with cardio-metabolic traits
or AD was associated with CIND susceptibility. We genotyped ~200,000 genetic variants
associated with multiple metabolic traits using the Cardio-MetaboChip (MetaboChip),
and 12 genetic variants strongly associated with AD susceptibility (including the APOE
isoform). We provide the first comprehensive genetic evaluation of CIND and
demonstrate a novel locus potentially increasing CIND susceptibility.

3.2 MATERIALS AND METHODS

3.2.1 Study cohort
This study was approved by University of Western Ontario Institutional Review Board
(Review number 07920E). The Canadian Study of Health and Aging (CSHA) was a
longitudinal population-based cohort study designed to document the prevalence of
dementia and related variables in elderly Canadian communities from 1991 to 2001
(n=10,263) (1994). CSHA participants were aged ≥65 years at the start of the study.
CIND patients (n=528) were selected based on clinical diagnoses of CIND based on
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria (American
Psychiatric Association. Task Force on DSM-IV., 1994) excluding patients with
presumed alcohol or drug use, mental retardation or other psychiatric illness. CIND
diagnoses were adjudicated by a panel of neuropsychologists and physicians during the
course of the CSHA, whereas control subjects (n=494) were selected from cognitively
normal CSHA participants. Modified Mini-Mental State Exam (3MS) (Teng and Chui,
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1987) scores obtained during the CSHA confirmed CIND and control status in patients
selected for this study.

3.2.2 Study design
We used a two-stage GWAS design comprising discovery and replication phases. The
discovery phase involved genotyping a cohort of CIND patients (n=274) and controls
(n=301) on the MetaboChip – a custom Illumina genotyping array (Illumina Inc.; San
Diego, CA) populated with ~200,000 single nucleotide polymorphisms (SNPs) identified
from

GWAS

of

metabolic

traits

and

(http://www.sph.umich.edu/csg/kang/MetaboChip/).

cardiovascular
MetaboChip

phenotypes

genotyping

was

performed at the Broad Institute (http://www.broadinstitute.org/). Variants included in
our analysis had call-rates >90%, minor allele frequency (MAF) >1% and Hardy
Weinberg P>10-4. The replication phase involved genotyping an independent cohort of
CIND patients (n=210) and controls (n=158) for the 13 most significant loci identified by
the MetaboChip. These variants were genotyped using either TaqMan SNP genotyping
assays (Applied Biosystems; Foster City, CA) or direct Sanger sequencing (Table 3.1). A
cohort of our study (339 cases, 304 controls) was also genotyped for the top 11 ADassociated variants using TaqMan genotyping assays (Table 3.1). The same quality
control filters applied in the discovery phase were applied to all genotyped variants.

3.2.3 Statistical analyses
Study cohort demographics were evaluated using chi-square (χ2) tests for dichotomous
variables and t-tests for continuous variables using SAS v9.2 (Cary, NC); statistical

rs1145909

rs1704405

ME1

EHD4

Y

N

N

Primer sequence
5’-TCCTTTCCAGGGTGCAAGTC-3’
5’-ATCTTCATTCAGCCCCAGAC-3’
5’-ATTGAGGATTCATTTGTGGC-3’
5’-AGCCCCTGTTTTTTACCTGTC-3’
5’-CCATCCCACATTTATGCAG-3’
5’-GCTTTTGGCAACCACTTTCTAG-3’
5’-TCAGACTTCACAAAGTGGGAATTTGA-3’
5’-TTGCCACTGCCCTTTGTCT-3’

NA

58oC annealing

56oC annealing

Conditions
58oC annealing

Primer sequence
Conditions
5’NA
AATGTAGTTAGCTTTAGTGTATGGTGTTTATAAAATCT3’
5’-CAGTGAGTGGTGAGCAAATGTG-3’
CD33
rs3865444
Y
5’-GAGTCGCAGCCTCACCTA-3’
NA
5’-CTCACACGGACCCTATAGAATCCTA-3’
SNPs not listed here were genotyped using pre-designed TaqMan SNP genotyping assays. The manufacturer’s suggested assay conditions were
used. NA, not applicable.

Alzheimer-related SNP genotyping assays
Gene
SNP
TaqMan
CD2AP
rs9349407
Y

rs13186537

IRX1

MetaboChip-related SNP genotyping assays
Gene
SNP
TaqMan
FLJ22536
rs16901621
N

Table 3.1 Custom variant genotyping assays and primer designs.
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significance was defined as P<0.05. Logistic regression was used to test for association
between

genetic

variants

and

CIND

status

using

PLINK

(http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al., 2007). Statistical significance
in the discovery phase was defined as a Bonferroni-corrected P<4.0x10-7. Our logistic
regression model was adjusted for potentially confounding variables including age, sex,
years of education, APOE ε4 carrier status, history of stroke or possible stroke and two
principal components of ancestry. The significance threshold for the replication phase
was set at P<3.8x10-3. Significance values reported for the combined cohort were used
only to show the change in significance with increasing sample size. It was not possible
to adjust for ancestry in the replication cohort; however it was unlikely to play a role. We
compared CSHA participant ancestry with HapMap populations of known ancestry
(2003) using identity-by-state and multidimensional scaling based on >50,000 variants to
confirm ancestry reported during the CSHA (Figure 3.1). Manhattan plots and quantilequantile (Q-Q) plots were used to visualize results using WGAViewer (Ge et al., 2008).
AD genetic risk scores (AD-GRS) were constructed using 11 AD-associated variants
identified from the largest AD GWAS meta-analyses (Hollingworth et al., 2011; Naj et
al., 2011). For each variant, 1 allele has been associated with AD risk (Odds ratio, OR,
>1.0) therefore in each participant, we counted the number of copies of risk alleles which
comprised a composite risk score. Risk alleles for the 11 AD-associated non-APOE
variants were identified based on data from the same meta-analyses (Bertram et al.). The
difference between mean AD-GRSs in cases and controls was tested using an
independent

samples

t-test

defining

statistical

significance

as

P<0.05.
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Figure 3.1 Principal components analysis with Canadian Study of Health and Aging
(CSHA)- and HapMap-derived populations. The first two principal components were
plotted with HapMap populations of known ancestry to confirm the reported ancestry of
CSHA participants. CEU (blue, n = 165), Caucasians; CSHA (black, n = 575), CSHA
discovery phase cohort; CHB/JPT (orange, n = 250), Chinese/Japanese; YRI (green, n =
203), African.
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3.2.4 Power calculations
For the discovery phase of our GWAS, we calculated a >80% probability of rejecting the
null hypothesis of no association for a common variant with strong biological effect
(OR=2.50, MAF=0.20) using a genome-wide level of Type I error probability. Based on
sample size in the replication phase and results from the GWAS discovery phase, we
estimated a <5% probability of rejecting the null hypothesis of no association for variants
of expected effect size and frequency (OR=1.50, MAF=0.30) using the Bonferronicorrected P-value of 3.8x10-3. When testing for association between AD-associated
variants and CIND, we calculated ~20% probability of rejecting the null hypothesis of no
association for a common variant with modest biological effect (OR=1.20, MAF=0.40)
using the standard level of Type I error probability. Power calculations were performed
using Power and Sample Size Calculation software (Dupont and Plummer, 1998).

3.3 RESULTS

3.3.1 Study subjects
Demographic data for CSHA participants selected for this study are shown in Table 3.2.
Cases and controls differed most significantly in 3MS score (P=6.8x10-38) and incident
stroke (P=6.9x10-4). Cases also had non-significantly higher frequencies of the remaining
indices of cardiovascular disease (CVD) compared to controls.

Combined
Discovery phase
Controls
CIND
Controls
CIND
459
484
301
274
n
45
45
46
46
Male (%)
75.6±6.6
76.4±6.5
76.2 ± 6.6
77.5±6.6
Age (±SD)
10.1±4.0
9.7±5.8
10.2±5.6
9.3±5.6
Education (years, ±SD)
88.0±7.5
80.2±9.9
88.5±9.6
81.8±9.6
3MS (±SD)
6.5
13.0
8.3
18.2
Stroke (%)
12.6
16.9
14.0
16.1
Diabetes mellitus (%)
50.8
55.2
49.5
52.9
Hypertension (%)
32.7
35.7
37.5
40.5
Circulation problems (%)
P-values are based on the combined cohort. 3MS, modified mini-mental state examination;
standard deviation.

Table 3.2 Study cohort demographics for CSHA controls and cases.
Replication phase
Controls
CIND
P-value
158
210
45
44
NS
74.4±6.5
75.1±6.2
NS
9.9±3.8
10.1±3.9
NS
88.5±6.3
83.1±9.0
6.8x10-38
3.2
6.7
6.9x10-4
10.1
18.1
0.07
53.2
58.1
NS
34.0
36.7
NS
NS, not significant (P-value>0.05); SD,
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3.3.2 GWAS of CIND
First, we tested for association between genetic variation in cardio-metabolic genes and
CIND status using the MetaboChip (Figure 3.2). The most significant CIND-associated
variant from the discovery phase was rs16901621 in FLJ22536 (OR=2.67; P=3.2x10-7)
which modestly surpassed the Bonferroni-corrected threshold of significance (P<4.0x107

). Given that no variants achieved stringent Bonferroni-corrected significance thresholds,

with exception to the FLJ22536 variant, we selected the 13 most significant variants
(P<1.0x10-3) for replication in an independent cohort (Table 3.3). We identified a locus
near ZNF608/GRAMD3 (rs1439568) approaching statistical significance for replication
(OR=0.66; P=6.0x10-3), however we were unable to replicate the initial finding in
FLJ22536 (OR=0.82; P=0.27) (Table 3.3). Although we observed similar effect sizes
between discovery and replication phase variants, no variants absolutely surpassed a
Bonferroni-adjusted

threshold

of

significance

(P<4.0x10-7).

The

rs1439568

polymorphism lies within a ~4kb haplotype block void of well-annotated genes, located
~500kb downstream of ZNF608 and ~115kb upstream of GRAMD3 (Figure 3.3). This
locus may represent a putative genetic determinant of CIND susceptibility.

3.3.3 AD-associated variation in CIND
Next, we sought to assess whether AD-related genetic variation was associated with
CIND. We genotyped 11 AD-associated variants reported in recent GWAS meta-analyses
of AD-related dementia (Hollingworth et al., 2011; Naj et al., 2011). No significant
associations were identified between any of the previously defined risk alleles, although
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Figure 3.2 Manhattan plot showing results from the MetaboChip genome-wide
association study in the discovery phase. Manhattan plots help visualize the loci
strongly associated with disease susceptibility by plotting all SNPs together based on
association P-value and physical position. Each point represents a P-value of a test for
association between a SNP and CIND status. The significance of association is plotted on
the y-axis with increasing significance ranking higher on the y-axis. The genomic
position of the SNP corresponding to each test for association is plotted on the x-axis.
Polymorphisms with P-values <10-3 are shown in red.
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rs1439568

rs1704405

rs556474

rs11023937

rs7518019

rs13186537

rs1145909

rs2615016

rs16901621

rs10898893

rs10275038

rs7574887

rs13218698

5

15

10

11

1

5

6

11

6

11

7

2

6

(2HR GLU)
IRX1
(MI/CAD)
ME1
(SBP)
SOX6
(LDL)
FLJ22536
(DBP)
FCHSD2
(NR)
DOCK4
(FAST GLU)
GEN1
(MI/CAD)
DOPEY1
(2HR GLU)

LOC553139

ZNF608/GRAMD3
(LDL)
EHD4
(QT)
CRTAC1
(DBP)
KCNQ1
(QT)

Nearest gene (trait)

C/A

G/A

A/G

G/A

G/A

C/G

A/C

A/C

G/A

G/C

A/G

G/A

Allele
(min/maj)
G/A

0.16

0.09

0.20

0.18

0.16

0.48

0.16

0.07

0.05

0.33

0.42

0.22

0.44

MAF

0.48 (0.34-0.69)

2.28 (1.48-3.52)

0.55 (0.40-0.75)

1.90 (1.39-2.59)

2.67 (1.83-3.90)

1.66 (1.29-2.13)

0.48 (0.33-0.68)

2.68 (1.62-4.45)

0.28 (0.14-0.53)

0.59 (0.45-0.77)

1.65 (1.29-2.12)

1.91 (1.40-2.60)

0.87 (0.59-1.30)
1.08 (0.81-1.46)
0.82 (0.58-1.17)
0.92 (0.64-1.33)
1.05 (0.72-1.53)
0.88 (0.55-1.41)
1.12 (0.77-1.62)

6.77x10-5
3.22x10-7
5.81x10-5
1.8x10-4
1.90x10-4
6.66x10-5

0.80 (0.34-1.84)

1.30x10-4

4.62x10-5

0.81 (0.59-1.10)

1.40x10-4

1.26 (0.71-2.23)

1.14 (0.85-1.52)

8.4610-5

1.30x10-4

1.24 (0.88-1.74)

0.56

0.59

0.79

0.67

0.27

0.59

0.50

0.43

0.60

0.18

0.40

0.22

Replication
OR
P
(95% CI)
0.66 (0.49-0.89)
0.0060

4.48x10-5

Discovery
OR
P
(95% CI)
0.62 (0.49-0.80)
1.60x10-4

Combined
(95%

0.74 (0.58-0.95)

1.51 (1.11-2.07)

0.72 (0.57-0.91)

1.44 (1.14-1.82)

1.49 (1.16-1.92)

1.35 (1.12-1.62)

0.64 (0.50-0.83)

1.99 (1.36-2.92)

0.41 (0.25-0.66)

0.69 (0.57-0.85)

1.43 (1.18-1.72)

1.54 (1.23-1.93)

CI)
0.66 (0.54-0.79)

OR

0.019

9.57x10-3

6.43x10-3

2.18x10-3

1.93x10-3

1.71x10-3

6.39x10-4

3.95x10-4

3.31x10-4

3.23x10-4

2.02x10-4

1.66x10-4

8.36x10-6

P

ORs and P-values are based on the minor allele. Risk alleles (OR>1.0) are underlined. 2HR GLU, two-hour blood glucose level; CHR, chromosome; DBP, diastolic blood pressure; FAST GLU,
fasting blood glucose level; LDL, low-density lipoprotein cholesterol level; MAF, minor allele frequency; maj, major (more frequent) allele; min, minor (less frequent) allele; MI / CAD,
myocardial infarction/coronary artery disease; NR, not reported; QT, QT interval; SBP, systolic blood pressure; SNP, single nucleotide polymorphism.

SNP

CHR

Table 3.3 Results from association tests between top MetaboChip variants and CIND status in discovery and replication phases.
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Figure 3.3 Regional genetic variation in the vicinity of rs1439568. A) Haplotype block
surrounding rs1439568 based on data from the HapMap CEU population. Red boxes
represent a high degree of linkage disequilibrium (LD) between two markers whereas
grey boxes suggest weak linkage disequilibrium. The relative position of rs1439568 is
outlined in red. By investigating LD between a variant of interest and additional nearby
variants, it is possible to better define the boundaries of a potential disease susceptibility
locus and whether regulatory elements fall within this locus such as a promoter region or
transcription factor binding sites. B) LD between MetaboChip genotyped SNPs and
rs1439568. Discovery phase-calculated p-values (left y-axis) for SNP association with
CIND determine the height of each point. The degree of LD between a SNP and
rs1439568 is proportional to the intensity of red colouration. Blue peaks identify sites of
recombination (right y-axis). When visualized together, this plot helps identify whether
the disease-associated SNP is in LD with other local SNPs and whether the local SNPs
were also associated with disease status. C) Regional LD between rs1439568 and
neighboring SNPs within 500 kilobases of rs1439568 based on the HapMap CEU dataset.
Each point represents a SNP and its height on the left y-axis indicates the strength of
linkage disequilibrium between a particular SNP and rs1439568. Blue peaks correspond
to sites of recombination (right y-axis). This plot provides an enhanced visualization of
local SNPs in LD with rs1439568 as this locus was more densely genotyped by the
HapMap consortium. Data from panels A) and C) were generated using the hg18 build.

A)

C)

B)
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the effect sizes for some variants, including CR1, ABCA7, and PICALM, were consistent
with previously published studies (Table 3.4). We also constructed a composite AD-GRS
using risk-increasing alleles from the AD-associated variants to assess an overall
difference in the accumulation of multiple AD-associated genetic variants between CIND
patients and controls (Figure 3.4). The frequencies of AD-GRSs between CIND patients
and controls were not significantly different when we compared mean scores, which
totaled ~9 risk alleles in CIND patients and controls (P=0.71). This suggests that putative
AD-associated variants are not involved in CIND predisposition.

3.3.4 APOE status in CIND
Finally, we evaluated the frequency of the APOE E4 allele in CIND patients versus
cognitively healthy controls. The frequency of the APOE E4 allele was elevated in CIND
patients versus controls. Each copy of the APOE E4 allele increased CIND susceptibility
compared to the APOE E3 allele (OR=1.35; P=0.044) (Table 3.5). The APOE E2 allele
frequency was non-significantly higher in cases versus controls (OR=1.14; P=0.44).

3.4 DISCUSSION

The principal finding of our study is that non-APOE genetic variation associated with
cardio-metabolic traits or AD is not associated with CIND susceptibility. We were not
able to identify any loci associated with CIND through a GWAS of >200,000 cardiometabolic-associated variants, nor were we able to replicate the top 11 non-APOE
variants associated with AD susceptibility either individually or as part of an AD-GRS.

SNP

Nearest
Allele
MAF
Reported OR
OR
P
gene
(min/maj)
(95%CI)
(95% CI)
1
rs3818361
CR1
A/G
0.18
1.16 (1.11-1.22)
1.27 (0.94 - 1.71)
0.12
8
rs11136000
CLU
T/C
0.41
1.12 (1.10-1.16)
0.90 (0.71 - 1.14)
0.39
19
rs3764650
ABCA7
G/T
0.09
1.23 (1.18-1.28)
1.14 (0.80 - 1.64)
0.47
11
rs3851179
PICALM
T/C
0.36
1.14 (1.09-1.16)
1.08 (0.86 - 1.37)
0.47
11
rs670139
MS4A4E
T/G
0.38
1.08 (1.05-1.10)
0.92 (0.74 - 1.15)
0.47
11
rs610932
MS4A6A
T/G
0.43
1.11 (1.08-1.14)
1.05 (0.76 - 1.19)
0.67
6
rs9349407
CD2AP
G/C
0.28
1.12 (1.07-1.17)
1.04 (0.82 - 1.32)
0.75
19
rs3865444
CD33
A/C
0.32
1.12 (1.09-1.16)
0.98 (0.78 - 1.23)
0.88
19
rs597668
EXOC3L2
C /T
0.14
1.17 (1.12-1.23)
1.01 (0.74 - 1.38)
0.95
7
rs11767557
EPHA1
C/T
0.19
1.12 (1.04-1.20)
1.00 (0.75 - 1.32)
0.99
2
rs744373
BIN1
G/A
0.29
1.17 (1.13-1.20)
1.00 (0.80 - 1.26)
0.99
Underlined alleles represent the previously reported risk alleles from genome-wide association study metaanalyses. Reported ORs represent meta-analyses from the AlzGene database (Bertram et al., 2013).
Abbreviations as in Table 3.3.
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Table 3.4 Results from association tests between Alzheimer disease-associated variants and CIND status.
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Figure 3.4 Frequency distribution of Alzheimer disease (AD) genetic risk scores in
cognitive impairment no dementia (CIND) patients and controls. Risk alleles from 11
non-APOE AD-associated variants were added in each study participant. For each
variant, a participant can have 0, 1, or 2 copies of the risk allele thus scores could range
from 0–22. Risk scores were calculated in CIND patients and controls. The difference
between the mean risk scores for CIND patients and controls was not different (P=0.71).
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APOE allele
Controls1 (%)
CIND2 (%)
OR (95% CI)
P-value
E2
85 (8.6)
99 (9.4)
1.14 (0.83-1.56)
0.44
E4
92 (9.3)
127 (12.0)
1.35 (1.00-1.81)
0.044
E3
807 (82.0)
828 (78.6)
NA
NA
1
n=492; 2n=527. Odds ratios (ORs) were calculated based on APOE allele frequency relative to
APOE E3 frequency. APOE, apolipoprotein E; CI, confidence interval; CIND, “cognitive
impairment no dementia”; NA, not applicable.

Table 3.5 APOE allele frequencies in CIND cases and controls.
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Despite these negative findings, we confirmed that the APOE E4 allele increases CIND
susceptibility. These contributions provide the most comprehensive genetic analysis of
CIND susceptibility conducted to date.

Our results provide some insight into the genetic basis of CIND. Our study
explicitly shows that the APOE E4 allele is associated with CIND susceptibility. Previous
studies have primarily evaluated CIND in the context of progression to late-stage
dementia phenotypes such as AD. For instance, one study of 68 CIND patients conducted
independently by the CSHA showed that APOE E4 carriers were 2.7-times more likely to
progress to AD (Hsiung et al., 2004). Other studies evaluating the APOE E4 allele in the
context of pre-dementia have used a phenotype called mild cognitive impairment (MCI)
that is known to progress to AD (Albert et al., 2011; Feldman and Jacova, 2005). Metaanalysis of 35 studies including 6095 MCI patients and 1236 AD patients reported an
association between the E4 allele in MCI to AD progression (P<0.001, OR=2.29, 95%
CI=1.88-2.80) (Elias-Sonnenschein et al., 2011). Our study is distinct in that we have
identified a similar but relatively modest association between the E4 allele and CIND
susceptibility in 527 CIND patients and 492 cognitively healthy controls (P=0.044,
OR=1.35, 95% CI = 1.00-1.81). Our data suggest that APOE E4 increases susceptibility
to CIND regardless of progression to late stage dementia, although with an effect size
approximately half of what is normally reported with disease progression. Such
differences in effect size may represent differences in sample size between studies, or
rather it may represent the underlying phenotypic heterogeneity within the clinical
definition of CIND, as discussed below. More careful evaluation of APOE is clearly
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needed to determine how the APOE E4 allele influences susceptibility to different forms
of cognitive decline.

We also show that VaD-related genetic variation is not associated with CIND.
Since VaD represents the second most common form of late-onset dementia, we used a
custom SNP array called the MetaboChip to investigate whether genetic loci associated
with vascular health including coronary artery disease, type 2 diabetes, and plasma lipid
concentrations were also associated with CIND. We were surprised to find no significant
association between genetic variation at cardio-metabolic loci and CIND since vascular
disease has an established correlation with cognitive decline (Gorelick et al., 2011).
Based on previous genetic studies in VaD, however, our findings may not be entirely
unexpected. A twin study assessing VaD showed little pair-wise concordance for VaD
suggesting a diminished role for genetics and a greater contribution of environmental
factors in VaD risk (Bergem et al., 1997). Furthermore, the only VaD GWAS has failed
to identify any loci surpassing a genome-wide threshold of significance (P<10-8) thus it is
possible that the variants associated with cardio-metabolic traits do not significantly
affect cognitive health or CIND susceptibility (Schrijvers et al., 2011).

Interestingly, we identified one variant near the ZNF608/GRAMD3 locus that was
nominally associated with CIND (P=0.0060, OR=0.66, 95% CI=0.49-0.89), although it
did not surpass stringent thresholds for association. ZNF608 was previously associated
with LDL cholesterol, which facilitated mapping of this locus on the MetaboChip.
GWAS have reported associations of common variants at ZNF608 with neuroblastoma
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and obesity (Speliotes et al., 2010). Differential ZNF608 expression has also been
observed in the prefrontal cortex during fetal and infant development (Colantuoni et al.,
2011). ZNF608 encodes a modestly characterized zinc-finger motif protein where
functional studies of the Drosophila melanogaster ZNF608 homologue, scribbler (sbb),
suggest a role for ZNF608 in transcriptional repression and starvation resistance
(Harbison et al., 2004). Additionally, ZNF608 contains ubiquitylation sites which suggest
a regulation of ZNF608 stability via post-transcriptional modification (PTM) (Wagner et
al., 2011). Conversely, our current understanding of the biological function of GRAMD3
is limited, thus the role of common variation at ZNF608/GRAMD3 in CIND susceptibility
is speculative at this point. Further association studies must be performed to confirm this
potential CIND susceptibility locus while sequencing of the ZNF608/GRAMD3 locus for
rare variant analysis may reveal insight into biological relevance by the identification of
functional variants.

Lastly, we were unable to extend associations previously reported between nonAPOE genetic variants associated with AD and the CIND phenotype. As a previous study
from the CSHA showed that CIND patients were 5 times more likely to develop AD than
cognitively normal participants (OR=5.0, 95% CI=3.4-7.3) (Tuokko et al., 2003), we
sought to test whether the top non-APOE AD-associated variants were associated with
CIND status. We found no significant association between established AD-associated
variants and CIND which was also confirmed in our AD-GRS analysis suggesting that
AD-related mechanisms of cognitive decline may not be a strong determinant of CIND.
The association between the APOE E4 allele and CIND proposes one commonality
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between CIND and AD, however, the effect size associated with the E4 allele in our
CIND cohort (OR=1.35, 95% CI=1.00-1.81) pales in comparison to the effect size
associated with the E4 allele in an AD meta-analysis of 37 studies (OR=3.68, 95%
CI=3.30-4.11) (Bertram et al.). Although we did not find strong evidence supporting a
similar genetic architecture between CIND and AD, an APOE-related pathway may be an
important determinant of susceptibility to cognitive decline in CIND.

A significant study limitation pertains to the phenotypic heterogeneity inherent in
CIND and pre-dementia. A spectrum of psychiatric diseases is associated with dementia
which extends to the onset of cognitive decline where a myriad of disease mechanisms
may initiate cognitive decline (Tarawneh and Holtzman, 2012; Tuokko et al., 2001).
Post-mortem studies of dementia patients commonly report mixed cerebrovascular and
AD-associated pathologies in patient brains, which supports a synergistic role for
multiple disease mechanisms in cognitive decline (Schneider et al., 2007). The spectrum
of disease severity among CIND patients further complicates the process of selecting an
ideally homogenous CIND cohort, since CIND patients have the potential to steadily
decline, remain stable or even improve cognitively (Tuokko et al., 2001). Within our
study cohort, we lacked the end-stage phenotyping required to diagnose a sub-type of
dementia such as VaD or AD, however, our study focused on the genetics of CIND
irrespective of dementia subtypes thus end-stage diagnosis was not a hindrance in our
study. In contrast, other studies that seek to characterize the transition from pre-dementia
to defined end-stage diseases will rely on the availability of prospective data and endstage phenotyping. The development of the MCI phenotype mirrors this logic as MCI
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was conceptualized as a pre-dementia stage specific to AD patients. Thus AD diagnosis
must be considered when studying MCI (Tarawneh and Holtzman, 2012).

Our study also had limited statistical power to detect significant associations with
small effect sizes. While our study of AD GWAS variants in CIND was negative, it is
important to note that the established non-APOE variants typically have small ORs
<1.20. Meta-analysis involving thousands of AD patients and controls was required to
achieve adequate statistical power to identify small but significant effect sizes; our study
was markedly underpowered to detect such effect sizes. In order to adapt our study to a
limited sample size, we implemented a two-stage GWAS approach in which we only
tested for association between cardio-metabolic loci within a population showing
normality according to our Q-Q plot (Figure 3.5). These approaches improved our ability
to detect a significant association by lowering the stringent statistical requirements
typical of true GWAS, however, the issue of limited statistical power was not
ameliorated. Based on the relatively larger effect size associated with the APOE E4 allele
in AD, our study was adequately powered to detect a significant association assuming a
similar effect size in CIND patients as observed in AD patients. Our AD GRS approach
also lowered statistical stringency as a P<0.05 specifies significance rather than a
Bonferroni-adjusted P-value cutoff applied to the individual tests for association (approx.
P<0.0045). In order to address the issue of power, larger CIND cohorts must be
organized, however ours is the largest genetic study of CIND patients conducted to date.
A sample size of ~3000 CIND patients and 3000 healthy controls would be required to
detect a significant association at the AD GWAS-identified BIN1 locus assuming a
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Figure 3.5 Quantile-quantile plot showing expected and observed p-values from the
MetaboChip discovery phase. QQ plots visualize the difference between the observed
P-values for each SNP derived from the GWAS discovery phase compared with expected
P-values derived from a theoretical χ2 distribution. The solid diagonal line represents the
null hypothesis of no difference between observed and expected P-values. Deviation from
the null hypothesis highlights the presence of inflation or deflation in observed P-values
which can be caused by the presence of unadjusted population stratification.

The

distribution of p-values suggests that there was no artificial inflation of test statistics
(λGC = 0.99).
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consistent effect size (OR=1.17). In comparison, a sample size of only 400 CIND patients
and 400 cognitively normal controls is required to replicate the putative association at the
ZNF608/GRAMD3 locus. Thus, it is clear that follow-up studies in CIND and predementia need to be on a similar scale as the scale of published AD GWAS in order to
detect associations of small effect. Finally, some limitations can also be attributed to our
use of the MetaboChip platform. Since only cardio-metabolic loci were included in our
GWAS, it is possible that we overlooked other loci that may contain genetic variation
associated with CIND. Imputation of additional variants or the application of a truly
genome-wide genotyping platform in a CIND cohort may provide a more comprehensive
investigation of genetic variation.

In summary, we have shown that genetic variation in cardio-metabolic and ADassociated loci are not associated with CIND. We identified a potential association
between the ZNF608/GRAMD3 locus and CIND status, however, additional studies are
required to validate this association as well as subsequent studies of possible functional
effects. Clinical implications arising from this study are hypothesis generating at this
stage. However, this novel approach to characterizing cognitive decline may help to
implicate a greater role for genetic determinants of cardiovascular traits when applied to
larger cohorts. While the synergy between cardiovascular and cognitive health is strong,
evidence in this study supporting a genetic link was weak. Identification of genes
contributing to cognitive decline via similar approaches as shown here will help us
understand the pathways and mechanisms affecting CIND susceptibility which will
ultimately guide future therapeutic strategies.
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CHAPTER 4

INVESTIGATING TYPE 2 DIABETES-ASSOCIATED COMMON VARIATION
IN ABORIGINAL POPULATIONS

4.1 INTRODUCTION

Globally, aboriginal and indigenous communities are facing an escalating type 2 diabetes
(T2D) epidemic. T2D was virtually non-existent amongst aboriginal populations decades
ago (Chase, 1937). However, aboriginal populations such as Ontario Oji-Cree now report
T2D in adults at an age-adjusted prevalence of ~26%, which ranks among the highest in
the world; aboriginal populations in Arizona, Oklahoma and the Dakotas reported notably
higher T2D frequencies of 38%, 40% and 40%, respectively (Yu and Zinman, 2007).
Adult Metis in Ontario have a reported diabetes frequency of 11%, which represents a
~25% increase above the national rate (Shah et al., 2011). Even the Canadian Inuit, who
historically were untouched by T2D, have now matched national standards for T2D
frequency based on a recent study of 36 Canadian Inuit communities (Egeland et al.,
2011). This significant and recent expansion of T2D prevalence in virtually all Canadian
aboriginal communities suggests that these populations may be at greater risk of T2D
compared to the non-aboriginal population.

Explanations for the recent rise in T2D cases among aboriginal people centre on
the significant lifestyle changes that Canadian aboriginals have gradually adopted. In
comparison to the traditional nomadic hunter-gatherer lifestyles of Canadian aboriginal
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groups, the pervasion of Western culture into aboriginal communities has increasingly
integrated non-traditional diets and lifestyles. Sedentary occupations and leisure
lifestyles, together with diets that have become increasingly high in sugar and fat, have
certainly contributed to the stark increase in T2D experienced by aboriginal Canadians
and this is reflected in the rising incidence of T2D particularly amongst aboriginal youth
(Millar and Dean, 2012; Sellers et al., 2009). Accordingly, nutritional and lifestyle
management strategies have been the primary initiatives in combating T2D in aboriginal
communities. Although an increase in T2D among aboriginal Canadians may not be
unexpected, given the relatively recent introduction of Western diets in aboriginal
communities, the rate at which T2D has exploded among Canadian aboriginals is
remarkable and has suggested that environmental factors are not entirely responsible for
the T2D epidemic. Thus prevailing hypotheses have implicated the role of genetic factors
in additionally modulating T2D susceptibility among aboriginal Canadians.

Indeed genetic variation has been associated with T2D susceptibility in aboriginal
Canadians. Hegele et al. identified a private, common variant in the hepatocyte nuclear
factor 1 homeobox A (HNF1A) gene in Ontario Oji-Cree descendants. Sequencing of
HNF1A, which encodes a transcription factor that regulates expression of several liverspecific genes, revealed a non-synonymous mutation of glycine to serine at amino acid
319 (p.G319S) (Hegele et al., 1999a). Almost 40% of adult T2D Oji-Cree patients
studied carried the p.G319S variant and these individuals were at increased risk of
diabetes, particularly T2D, as p.G319S lowered the T2D age at onset following a gene
dosage effect. Subsequent in vitro functional analyses of the p.G319S variant suggested
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lowered insulin secretion due to a combination of reduced HNF1A mRNA expression via
the introduction of alternative splicing events as well as reduced HNF1A transactivation
activity (Bjorkhaug et al., 2005; Harries et al., 2008). The p.G319S variant provided
evidence of a private T2D susceptibility variant among the Oji-Cree and spurred the
search for additional genetic variants that may also contribute to T2D risk in the Oji-Cree
and indeed other aboriginal populations.

Additionally, Hegele et al. used a genome-wide scan using 190 microsatellite
markers to agnostically investigate additional T2D susceptibility loci in the Oji-Cree
(Hegele et al., 1999b). Although this initial scan revealed potential T2D susceptibility
loci, the study was limited in terms of genome coverage and resolution. More recently,
genome-wide association studies (GWAS) have been used to identify T2D-related loci by
testing for genetic association using markers of common variation known as single
nucleotide polymorphisms (SNPs) that occur approximately every 300 nucleotides across
the genome. To date, the largest T2D GWAS have involved cohorts of European and
Asian descent (Kooner et al., 2011; Voight et al., 2010). Testing for association between
T2D and millions of SNPs in multi-ethnic populations has identified several T2Dassociated loci which have implicated pathways related to β-cell dysfunction and insulin
secretion in modulating T2D risk (Voight et al., 2010). Additional GWAS on glycemic
traits have confirmed overlap between at least five T2D susceptibility loci and fasting
blood glucose (FBG)-associated loci suggesting shared biological mechanism between
disease status and disease-related clinical trait (Billings and Florez, 2010). Surprisingly,
relatively few genetic studies have been performed within aboriginal communities despite
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global aboriginal populations showing remarkable increases in T2D frequency (Yu and
Zinman, 2007).

Using T2D GWAS meta-analyses from European and South Asian cohorts, we
sought to investigate the frequencies of established T2D-associated variants in a subset of
Canadian aboriginal populations. Our primary objective was to test for association
between established T2D-associated variants and T2D status in 2 Canadian aboriginal
populations; the Oji-Cree of Sandy Lake, Ontario and the Inuit of Inuvik, Northwest
Territories. We also tested for association between T2D variants and FBG in Sandy Lake,
Inuvik and Greenland non-diabetic aboriginal populations. Our secondary objective was
to compare the accumulation of T2D variants in T2D patients and controls from the
Sandy Lake and Inuvik populations in the form of a composite genetic risk score (GRS).
We demonstrate that the established T2D-associated variants are not strongly associated
with T2D in either of these Canadian aboriginal populations individually or as part of a
risk score. However, the Inuvik Inuit T2D patients showed a significantly higher risk
score based on South Asian-identified T2D variants compared to non-diabetic Inuvik
controls. Furthermore, a South Asian-identified T2D-associated variant in the gene
encoding high mobility group 20A (HMG20A) was significantly associated with FBG in
a combined cohort of Inuvik and Greenland Inuit suggesting a potential T2D
susceptibility locus common between South Asians and Inuit.
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4.2 MATERIALS AND METHODS

4.2.1 Study populations
All individuals involved in this study gave informed consent and the use of the DNA
samples given for research was approved by the University of Western Ontario Research
Ethics Board for Health Sciences Research Involving Human Subjects (Review number
07920E, Appendix A-1). Study participants were randomly sampled from 2 Canadian
aboriginal groups and 1 Greenland Inuit group. Relevant demographic data are listed in
Table 4.1. Participants of Oji-Cree descent from Sandy Lake (n=399), Ontario were
randomly selected from the Sandy Lake Health and Diabetes Project (Harris et al., 1997).
Fasting blood samples were collected at the time of the health study in order to measure
plasma glucose as well as for DNA extraction. Participants of Inuit descent (n=282) were
randomly selected from the Inuvik Inuit community of the Northwest Territories as well
as Greenland and Denmark (n=187) (Bjerregaard et al., 2003).

4.2.2 Study design
Using clinical diagnoses of T2D, we performed tests for association between a panel of
17 T2D GWAS-identified SNPs and T2D status (Table 4.2). We performed this study
with Sandy Lake T2D cases (n=68) and controls (n=320) in addition to Inuvik T2D cases
(n=13) and controls (n=247). FBG concentrations were also available for the Sandy Lake
(n=321), Inuvik (n=136), and Greenland (n=187) populations. Within each population,
we tested for association between blood glucose concentration and T2D-associated SNP
genotypes. Whole-genome amplified DNA samples from each aboriginal group were
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Table 4.1. Canadian aboriginal study population demographics.
Sandy Lake
Inuvik
Greenland
n
399
282
187
Male (%)
44
33
40
Diabetic (%)
17.5
4.6
n.d.
Age (years)
29±16
45±16
43±15
BMI
27±6
31±7
26±5
TG (mmol/L)
1.4±0.7
1.74±1.3
1.0±0.5
Fasting glucose (mmol/L)
6.3±2.9
5.3±0.8
5.7±0.9
BMI, body mass index; n.d., no data; TG, triglyceride concentration.

rs4607103

rs1801282

3

3

PPARG

ADAMTS9

Nearest
Gene

rs3923113

2

GRB14

Nearest
Gene
165,210,095

Position

185,511,687
20,661,250
28,180,556
118,184,783
22,134,094
94,462,882
114,758,349
17,409,572
71,663,102

12,393,125

64,711,904

Position

C/A

Alleles
(min/maj)

T/G
C/G
C/T
T/C
C/T
T/C
T/C
T/C
C/T

G/C

T/C

Alleles
(min/maj)

nr
nr
nr
0.76
nr
nr
0.30
nr
nr

nr

SA
nr

0.64

EU

0.74

SA

RAF

0.29
0.31
0.50
0.65
0.83
0.53
0.26
0.47
0.27

0.86

EU
0.76

RAF

1.08

OR

1.14
1.12
1.10
1.12
1.20
1.13
1.37
1.14
1.09

1.14

1.09

OR

Reference
(Kooner et
al., 2011)
1.6x10-9

(Zeggini et
al., 2008)
(Saxena et
al., 2010)

Reference

P-value

8.9x10-16
4.1x10-11
5.0x10-14
5.3x10-8
7.8x10-15
5.7x10-10
1.0x10-48
6.7x10-11
1.1x10-9

1.7x10-6

1.2x10-8

P-value

3
rs16861329
ST6GAL1
188,149,155
A/G
0.86 0.75
1.08
1.3x10-7
10
rs1802295
VPS26A
70,601,480
A/G
0.31 0.26
1.07
2.1x10-8
15
rs7178572
HMG20A
75,534,245
A/G
0.71 0.52
1.08
9.2x10-13
15
rs2028299
AP3S2
88,175,261
C/A
0.31 0.31
1.08
1.2x10-11
20
rs4812829
HNF4A
42,422,681
A/G
0.19 0.29
1.09
8.2x10-12
CHR, chromosome; EU, European; maj, major or more frequent allele; min, minor or less frequent allele; OR, odds ratio; RAF, risk
allele frequency; SA, South Asian. Risk alleles are underlined.

SNP

CHR

3
rs4402960
IGF2BP2
6
rs7754840
CDKAL1
7
rs864745
JAZF1
8
rs13266634
SLC30A8
9
rs10811661 CDKN2A/2B
10
rs1111875
HHEX
10
rs7903146
TCF7L2
11
rs5219
KCNJ11
12
rs7961581
TSPAN8
South Asian-identified T2D variants

SNP

CHR

European-identified T2D variants

Table 4.2 Top T2D-associated variants identified by GWAS in European and South Asian cohorts.
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Variants included in our analysis had call-rates >90%, minor allele frequency (MAF)
>1% and were in Hardy Weinberg equilibrium (P>0.05). The 17 T2D SNPs were
cumulatively assessed as a composite GRS in order to assess the combined effect of these
variants on T2D susceptibility as well as FBG concentration.

4.2.3 Statistical analyses
Study cohort demographics were evaluated using chi-square (χ2) tests for dichotomous
variables and t-tests for continuous variables using SAS v9.2 (Cary, NC); the nominal
level of statistical significance was set at P<0.05. Logistic regression was used to test for
association

between

T2D

variants

and

T2D

status

using

PLINK

(http://pngu.mgh.harvard.edu/purcell/plink/). Statistical significance was defined as a
Bonferroni-corrected P<0.0029. Our logistic regression model was adjusted for
potentially confounding variables including age, sex, body-mass index (BMI) and
aboriginal population status in analyses combining populations. Similarly, our linear
regression model was adjusted for age, sex, BMI and aboriginal population status when
combining aboriginal populations. ~200,000 SNP genotypes were available for a subset
of Inuvik Inuit (n=142) from genotyping on the custom Cardio-Metabochip genotyping
array (Illumina Inc.; San Diego, CA) which were used to perform identity-by-state and
multidimensional scaling experiments within this specific subset of Inuvik Inuit (Figure
4.1). Genetic risk scores were constructed using study participants with complete
genotyping for the 17 T2D-associated SNPs. As each SNP includes an allele associated
with T2D risk, each participant’s risk score reflects the sum of T2D-associated risk
alleles for each of the 17 SNPs. Mean risk scores were compared between T2D patients
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Figure 4.1 Principal components analysis with Inuvik and HapMap-derived
populations. The first two principal components were plotted with HapMap populations
of known ancestry to compare the reported ancestry of Inuvik participants. CEU (green,
n=267),

Caucasians;

INV

(orange,

n=146),

Inuvik;

CHB/JPT (red,

n=250),

Chinese/Japanese; GIH, (blue, n=101), East Indian; YRI, (purple, n=203), African.
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and healthy controls using t-tests. Risk scores for non-diabetics were also compared with
FBG concentrations by creating risk score bins and calculating mean FBG concentrations
per risk score bin. The strength of correlation between risk score and FBG concentrations
was judged based on the r2 value for the line of best fit where statistical significance was
defined by P<0.05.

4.2.4 Power calculations
In order to have at least 80% power to detect a true positive association for a SNP
representative of our SNP panel (MAF=0.20, OR=1.09, P=0.05), our study required
approximately 8000 T2D patients and 32,000 healthy controls. Relative to these
calculations, our study cohort was considerably underpowered. However, no Aboriginalbased populations or databases currently exist that would meet these requirements for
adequate statistical power. Power calculations were performed using Power and Sample
Size Calculation software (Dupont and Plummer, 1990).

4.3 RESULTS

4.3.1 Study participants
Demographic data for each aboriginal group tested for association is shown in Table 4.1.
T2D status was only available for the Sandy Lake Oji Cree and Inuvik Inuit. Based on
these population samples, the Sandy Lake Oji Cree sample showed the highest frequency
of T2D participants at 17.5%, which recapitulated the notoriously high T2D prevalence
reported in the greater Sandy Lake aboriginal population; mean FBG was also highest
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among the Sandy Lake Oji Cree. T2D frequency within the Inuvik Inuit sample was
comparatively low, which was representative of the low T2D frequency observed in the
greater Inuvik Inuit population.

4.3.2 Establishing T2D variant frequencies in aboriginal populations
First, we sought to determine allele frequencies for each of our candidate T2D variants in
our aboriginal study populations. As variant frequencies are known to differ across multiethnic populations, we were not surprised to observe variance in T2D risk-associated
allele frequencies between the three aboriginal populations and the reference European
and South Asian populations (Table 4.3). While the majority of variants showed similar
allele frequencies across all study and reference populations, it was interesting to observe
considerable decreases in risk allele frequencies for variants near TSPAN8 and AP3S2
when comparing the European and South Asian cohorts versus our aboriginal study
populations. Furthermore, it was also noteworthy that the HNF4A risk allele represented
the minor allele in the reference populations but approached or attained major allele
status within our aboriginal study populations.

4.3.3 Replication of T2D variant associations in aboriginal populations
First, we tested for association between 17 T2D-associated SNPs and T2D status in the
Sandy Lake Oji Cree and Inuvik Inuit samples. T2D patients from both aboriginal groups
showed significantly higher BMI, TG and fasting glucose compared to controls as
expected. T2D patients were also, on average, significantly older than controls (Table
4.4). Our logistic regression analysis failed to replicate association that approached

European-identified T2D variants
RAF
Nearest
Alleles
CHR
SNP
Gene
(min/maj)
EW
SA
SL
3
rs4607103
ADAMTS9
T/C
0.76
nr
0.62
3
rs1801282
PPARG
G/C
0.86
nr
0.92
3
rs4402960
IGF2BP2
T/G
0.29
nr
0.20
6
rs7754840
CDKAL1
C/G
0.31
nr
0.36
7
rs864745
JAZF1
C/T
0.50
nr
0.67
8
rs13266634
SLC30A8
T/C
0.65
0.76
0.86
9
rs10811661 CDKN2A/2B
C/T
0.83
nr
0.91
10
rs1111875
HHEX
T/C
0.53
nr
0.34
10
rs7903146
TCF7L2
T/C
0.26
0.30
0.14
11
rs5219
KCNJ11
T/C
0.47
nr
0.16
12
rs7961581
TSPAN8
C/T
0.27
nr
0.01
South Asian-identified T2D variants
RAF
Nearest
Alleles
CHR
SNP
Gene
(min/maj)
EW
SA
SL
2
rs3923113
GRB14
C/A
0.64
0.74
0.95
3
rs16861329
ST6GAL1
A/G
0.86
0.75
0.43
10
rs1802295
VPS26A
A/G
0.31
0.26
0.15
15
rs7178572
HMG20A
A/G
0.71
0.52
0.40
15
rs2028299
AP3S2
C/A
0.31
0.31
0.02
20
rs4812829
HNF4A
A/G
0.19
0.29
0.78
Abbreviations as in Table 4.2. SL, Sandy Lake; IN, Inuvik; and GR, Greenland.

Table 4.3 Putative T2D risk allele frequencies in select aboriginal populations.

RAF
IN
0.85
0.77
0.63
0.56
0.15
0.43

GR
0.84
0.78
0.37
0.69
0.14
0.55

RAF
IN
GR
0.62
0.76
0.82
0.86
0.26
0.25
0.41
0.48
0.50
0.54
0.55
0.67
0.64
0.79
0.42
0.65
0.11
0.11
0.27
0.49
0.05
0.13
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Sandy Lake
T2D
Non-T2D
P-value
n
68
320
n.a.
% Male
42
45
n.s.
Age (years)
45±15
26±14
<0.0001
BMI
31±5
26±6
<0.0001
TG (mmol/L)
2.1±0.9
1.26±0.62
<0.0001
Fasting glucose (mmol/L)
10.8±4.7
5.41±0.55
<0.0001
P-values are based on t-tests performed between T2D and non-T2D patients.
T2D
13
31
65±8
33±5
2.8±1.9
6.9±1.7

Inuvialuit
Non-T2D
247
32
43±15
30±7
1.7±1.2
5.2±0.6

Table 4.4 Demographics for T2D and non-T2D patients in two aboriginal Canadian populations.

P-value
n.a.
n.s.
<0.0001
n.s.
0.0035
<0.0001
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nominal significance in either of the Sandy Lake Oji Cree or the Inuvik Inuit cohorts,
although some variants, such as those in PPARG and KCNJ11, replicated similar effect
sizes as those previously observed in GWAS meta-analysis (Table 4.5).

4.3.4 Association between T2D variants and fasting blood glucose
Next, we tested for association between the 17 T2D-associated SNPs and FBG using an
adjusted linear regression model including non-T2D patients from the Sandy Lake Oji
Cree, Inuvik Inuit and the Greenland Inuit cohorts (Table 4.6). The Sandy Lake Oji Cree
cohort showed associations of nominal significance (P<0.05) for variants at the CDKAL1,
CDKN2A/2B, and RPS26A loci. The Inuvik Inuit cohort showed associations of nominal
significance at the ADAMTS9, TCF7L2, TSPAN6, and HMG20A loci. The Greenland
Inuit cohort showed only one association of nominal significance at the HMG20A locus.
Because the Inuvik and Greenland Inuit share similar ancestry, both cohorts were merged
(n=436) and re-analyzed using a linear regression model adjusted for covariates as well
as population identity. The combined analysis showed that each copy of the T2Dassociated variant in HMG20A, also the major allele, was associated with a 0.18 mmol/L
increase in FBG (P=1.6x10-4). The significance of this association in the combined Inuit
cohort surpassed a Bonferroni-corrected level of significance (P<2.9x10-3). This
association suggests a potential biological connection between a T2D susceptibility locus
and FBG concentration in Inuit descendants. Further assessment is required in additional
Inuit cohorts to confirm this association.

Table 4.5 Association between established T2D variants and T2D status in aboriginal Canadian populations.
Sandy Lake
Inuvialuit
Allele
Ref.
OR
OR
CHR
SNP
Nearest gene
P-value
P-value
(min/maj) OR
(95% CI)
(95% CI)
2
rs3923113
GRB14
C/A
1.08 0.53 (0.15 – 1.92)
0.33
2.02E-08 (0 – ∞)
0.99
3
rs1801282
PPARG
G/C
1.14 1.11 (0.53 – 2.34)
0.78
0.61 (0.15 – 2.43)
0.49
3
rs4607103
ADAMTS9
T/C
1.09 1.13 (0.75 – 1.71)
0.56
1.35 (0.50 – 3.66)
0.55
3
rs4402960
IGF2BP2
T/G
1.14 0.84 (0.50 – 1.41)
0.52
0.59 (0.20 – 1.76)
0.35
3
rs16861329
ST6GAL1
A/G
1.08 0.84 (0.56 – 1.27)
0.41
1.51 (0.55 – 4.15)
0.43
6
rs7754840
CDKAL1
C/G
1.12 1.01 (0.66 – 1.55)
0.96
0.65 (0.24 – 1.75)
0.40
7
rs864745
JAZF1
C/T
1.10 0.90 (0.57 – 1.42)
0.65
1.47 (0.55 – 3.94)
0.44
8
rs13266634
SLC30A8
T/C
1.12 0.91 (0.49 – 1.71)
0.77
1.73 (0.65 – 4.61)
0.27
9
rs10811661 CDKN2A/2B
C/T
1.20 1.46 (0.74 – 2.85)
0.27
0.76 (0.27 – 2.11)
0.60
10
rs1802295
VPS26A
A/G
1.07 1.57(0.83 – 2.90)
0.16
0.98 (0.36 – 2.62)
0.96
10
rs1111875
HHEX
T/C
1.13 1.40 (0.87 – 2.26)
0.16
1.44 (0.54 – 3.85)
0.46
10
rs7903146
TCF7L2
T/C
1.37 0.92 (0.51 – 1.65)
0.77
0.95 (0.25 – 3.65)
0.95
11
rs5219
KCNJ11
T/C
1.14 1.36 (0.75 – 2.50)
0.31
1.06 (0.41 – 2.70)
0.91
12
rs7961581
TSPAN8
C/T
1.09 2.11E+08 (0 – ∞)
0.99
6.09E+07 (0 – ∞)
0.99
15
rs7178572
HMG20A
A/G
1.08 0.72 (0.47 – 1.11)
0.13
0.54 (0.21 – 1.43)
0.23
15
rs2028299
AP3S2
C/A
1.08 0.83 (0.20 – 3.44)
0.80
0.62 (0.14 – 2.78)
0.53
20
rs4812829
HNF4A
A/G
1.09 0.65 (0.37 – 1.12)
0.12
1.02 (0.38 – 2.78)
0.98
P-values shown are based on established risk allele (underlined) and adjusted for sex, age, and body mass index.
Abbreviations as in Table 4.1.
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rs3923113

rs4607103

rs1801282

rs4402960

rs16861329

2

3

3

3

3

ST6GAL1

IGF2BP2

PPARG

ADAMTS9

GRB14

A/G

T/G

G/C

T/C

C/A

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

-0.020
0.041
0.045
0.067

0.037
0.016
-0.051
-0.0078

-0.027
0.13
0.080
0.11

-0.011
-0.12
0.050
-0.066

-0.032
-0.10
0.061
-0.051

0.039
0.066
0.10
0.058

0.048
0.061
0.096
0.055

0.077
0.071
0.12
0.065

0.039
0.059
0.10
0.054

0.091
0.076
0.12
0.067

0.62
0.54
0.60
0.25

0.44
0.80
0.60
0.89

0.73
0.067
0.50
0.089

0.77
0.041
0.63
0.23

0.72
0.19
0.60
0.45

Table 4.6 Association between established T2D variants and fasting blood glucose in three
aboriginal populations.
CHR
SNP
Nearest
Allele
Population
β
SE
P-value
Gene
(min/maj)
(mmol/L)
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rs7754840

rs864745

rs13266634

rs10811661

rs1111875

6

7

8

9

10

Table 4.6 continued.
CHR
SNP

HHEX

CDKN2A/2B

SLC30A8

JAZF1

CDKAL1

Nearest
Gene

T/C

C/T

T/C

C/T

C/G

Allele
(maj/min)

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

Population

-0.016
0.0074
0.026
0.033

0.15
-0.0093
-0.00037
-0.00043

0.030
-0.040
0.076
0.0055

-0.052
-0.0025
0.094
0.025

0.10
-0.033
-0.017
-0.040

β
(mmol/L)

0.042
0.056
0.087
0.049

0.069
0.053
0.11
0.052

0.062
0.055
0.096
0.051

0.041
0.055
0.089
0.049

0.039
0.057
0.082
0.048

SE

0.71
0.89
0.76
0.50

0.030
0.86
0.99
0.99

0.63
0.47
0.43
0.91

0.21
0.96
0.29
0.61

0.015
0.56
0.84
0.41

P-value
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rs7903146

rs1802295

rs5219

rs7961581

rs7178572

10

10

11

12

15

Table 4.6 continued.
CHR
SNP

HMG20A

TSPAN8

KCNJ11

VPS26A

TCF7L2

Nearest
Gene

A/G

C/T

T/C

A/G

T/C

Allele
(maj/min)

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

Population

0.053
0.13
0.26
0.18

-0.052
-0.25
-0.039
-0.14

-0.016
-0.062
0.11
0.034

-0.10
-0.050
-0.011
-0.035

-0.086
0.19
-0.073
0.086

β
(mmol/L)

0.039
0.052
0.086
0.048

0.17
0.12
0.13
0.088

0.052
0.060
0.082
0.050

0.052
0.057
0.095
0.052

0.058
0.081
0.16
0.079

SE

0.18
0.017
2.1x10-3
1.6x10-4

0.76
0.037
0.76
0.11

0.76
0.30
0.17
0.50

0.044
0.38
0.91
0.50

0.14
0.024
0.64
0.28

P-value
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rs4812829

20

HNF4A

AP3S2

Nearest
Gene

A/G

C/A

Allele
(min/maj)

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

Sandy Lake
Inuvialuit
Greenland
Comb. Inuit

Population

0.028
0.020
-0.072
-0.019

0.052
0.085
0.10
0.10

β
(mmol/L)

0.049
0.056
0.088
0.050

0.16
0.082
0.12
0.070

SE

0.57
0.72
0.42
0.70

0.74
0.30
0.39
0.15

P-value

Values presented from a linear regression model adjusted for age, sex, body mass index and
population identity (combined analysis only). Inuvialuit and Greenland populations were combined
and re-analysed. Underlined alleles represent established type 2 diabetes-associated risk alleles.
β,effect size; SE, standard error. Comb., combined samples. Remaining abbreviations as in Table
4.1.

rs2028299

15

Table 4.6 continued.
CHR
SNP
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4.3.5 T2D genetic risk scores in aboriginal populations
Finally, we tested whether T2D patients from the Sandy Lake Oji Cree and Inuvik Inuit
cohorts carried a significantly greater accumulation of multiple T2D-associated variants
through the use of a composite GRS. There was no significant difference between mean
risk scores using all 17 SNPs for T2D patients and healthy controls in either the Sandy
Lake Oji Cree or Inuvik Inuit cohorts. As a sub-analysis, we sub-divided risk scores
based on T2D SNPs identified in either the European or South Asian cohort metaanalyses. No significant difference was observed in either the Sandy Lake Oji Cree or
Inuvik Inuit cohorts based on the European T2D SNP risk score. Conversely, we
observed a nominally significant difference in mean South Asian-derived risk scores
between Inuvik Inuit T2D patients and healthy controls (Table 4.7, Figure 4.2C). The
same South Asian risk score adjusted for the reported effect sizes for each risk allele
produced a similar nominally significant result (Table 4.7). We further tested whether
risk score correlates with FBG independently in combined non-diabetic Inuvik (n=184)
and Greenlanders of unknown diabetic status (n=159) using regression analysis; however
no association was identified (Figure 4.3).

4.4 DISCUSSION

The principal finding of our study is that established T2D-associated variants are not
associated with T2D status in Canadian aboriginal patients. We were unable to replicate
associations between 17 GWAS-identified T2D variants and the Sandy Lake Oji-Cree or
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Table 4.7 Genetic risk scores in T2D and non-T2D patients in two aboriginal
Canadian populations.
Non-weighted
Sandy Lake

Inuvik Inuit

GRS type
European
South Asian
Cumulative

Non-T2D GRS
10.4±0.1
4.4±0.1
14.8±0.1

T2D GRS
10.1±0.3
4.3±0.2
14.4±0.3

P-value
0.29
0.74
0.28

European
South Asian
Cumulative

11.2±0.1
7.2±0.1
18.4±0.2

10.8±0.6
8.1±0.3
18.9±0.6

0.48
0.049
0.51

GRS type
European
South Asian
Cumulative

Non-T2D GRS
11.7±0.1
4.8±0.09
16.5±0.2

T2D GRS
11.4±0.3
4.7±0.2
16.1±0.4

P-value
0.29
0.74
0.28

Weighted
Sandy Lake

12.4±0.2
12.0±0.7
0.61
European
7.8±0.1
8.8±0.4
0.049
South Asian
20.5±0.2
20.9±0.7
0.58
Cumulative
Mean risk scores are shown ± standard deviation in cohorts of T2D patients and
healthy controls. GRS, genetic risk score.
Inuvik Inuit
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Figure 4.2. Frequency distributions of non-weighted T2D risk scores in Inuvik T2D
patients and healthy controls. Inuvik T2D patients (n=11) and healthy Inuvik controls
(n=184) with complete genotyping were included. A) Combined risk scores were
calculated using a total of 17 T2D variants identified in both European and South Asian
cohorts (min. score=0, max. score=34). Mean risk scores between T2D patients and
controls, 18.9 and 18.4 respectively, were non-significant (P=0.51). B) European-derived
risk scores included 11 T2D variants identified in T2D GWAS in European cohorts (min.
score=0, max. score=22). Mean risk scores between T2D patients and controls, 10.8 and
11.2 respectively, were non-significant (P=0.48). C) South Asian-derived risk scores
included 6 T2D variants identified by T2D GWAS in South Asian cohorts (min. score=0,
max. score=12). Mean risk scores between T2D patients and controls, 8.1 and 7.2
respectively, were non-significant (P=0.05). Statistics were calculated using Student’s ttest.
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Figure 4.3. Correlation between fasting blood glucose and T2D genetic risk score.
Mean fasting blood glucose (FBG) values are plotted for participants sorted into bins of
genetic risk score based on 17 T2D variants. Non-diabetics from Inuvik Inuit (n=184) and
Greenland Inuit (n=159) populations with complete genotyping for 17 T2D variants were
included. However, no significant association was observed (P=0.45). Statistics were
calculated from a linear regression model.

138

139

Inuvik Inuit T2D patients. Our T2D GRS analysis supported this finding, however,
Inuvik Inuit T2D patients showed a modestly higher accumulation of South Asian T2D
risk alleles compared to controls. One significant association was detected between a
T2D-associated variant from the HMG20A locus (rs7178572) and FBG in the two Inuit
populations studied here which suggests a potential T2D-related susceptibility locus
common between South Asians and Inuit descendants.

Our study provides novel insight into T2D susceptibility amongst aboriginal
Canadians. The largest GWAS of T2D loci to date have focused on cohorts of European,
East Asian and South Asian descent and have successfully identified several T2D
susceptibility loci of modest effect. Previous genetic studies in aboriginal Canadian
populations, guided by a candidate gene approach, identified variants associated with
T2D risk and so we sought to apply a similar approach by investigating the top common
variants from T2D GWAS in aboriginal Canadian populations. Using a case-control
approach in Sandy Lake Oji-Cree and Inuvik Inuit samples, we were unable to replicate
previous GWAS-identified associations with T2D. This was not entirely unexpected
given statistical limitations due to small sample size involved as well as issues
surrounding the replicability of GWAS-identified variants in multi-ethnic populations.
The prevailing concept regarding GWAS findings suggests that the top variant at a locus
tags additional variants through linkage disequilibrium. Between multi-ethnic
populations, however, patterns of linkage disequilibrium differ and so GWAS-identified
risk variants may vary from population to population as variant frequencies also differ
(Cooper et al., 2008; Fu et al., 2011). Thus, it remains possible that the top T2D loci from
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European and South Asian cohorts may not directly translate to T2D susceptibility in
Canadian aboriginal populations.

In addition to the dichotomous analysis of T2D status, GWAS have investigated
the role of common variation in modulating clinical T2D-related traits such as FBG.
These studies, performed in participants without diabetes, were initiated to develop better
understanding of the biological pathways involved in regulating diabetes-related
quantitative traits. Cumulatively, common variation explains ~10% of the inherited
variation in FBG concentration suggesting a modest role for common variation in FBG
variability (Dupuis et al., 2010). As several loci have been associated with both T2D
status and FBG, such as GCKR, MTNR1B and TCF7L2, we tested whether our panel of
top T2D-associated variants was associated with FBG in three aboriginal populations.
Although our findings were largely negative, we identified a modest association between
the South Asian-identified HMG20A locus (rs7178572) and FBG. In a combined cohort
of Inuvik Inuit and Greenland Inuit, we observed that the T2D risk allele for this variant
was also associated with a 0.18 mmol/L increase in FBG per copy of the T2D risk allele
(P=1.6x10-4). As this trend was not observed in the Sandy Lake Oji-Cree sample, our
findings suggest that this variant may be unique to South Asian and Inuit descendants
however, further validation is required. The observed effect of the HMG20A variant on
FBG is almost twice that reported by the top GWAS-identified loci on FBG (β= ~0.07
mmol/L) although the clinical relevance of such an effect is not clear.
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Although our study is the first to test for association between established T2D
variants and T2D status as well as FBG concentration, our findings must be considered
within the context of specific limitations. First, our statistical power to detect associations
between the 17 T2D-associated variants and T2D was limited by sample size. The T2D
variants featured in our study were identified in cohorts that included thousands of
participants which is essential to detecting significant associations of small effect size.
Due to the limited sample size of the aboriginal populations featured in our study, we
cannot rule out the potential for these 17 T2D variants in playing a role in T2D
susceptibility among Canadian aboriginals. Furthermore, the modest association detected
between the HMG20A variant and FBG, while notable, also requires additional validation
given our limited statistical power.

Secondly, our approach which targeted GWAS-identified T2D loci is likely to
have excluded additional loci that may be uniquely associated with Canadian aboriginal
populations. The application of GWAS to a Canadian aboriginal population would
facilitate an agnostic search for T2D susceptibility loci, however, the sticking point
remains identifying a sizable population to afford adequate statistical power. One option
that may help in addressing this issue may be combining aboriginal populations with
related ancestry such as the circumpolar Inuit populations.

Thirdly, previous studies have shown that there is often difficulty in replicating
GWAS findings across multi-ethnic populations (Cooper et al., 2008; Fu et al., 2011;
Imamura and Maeda, 2011). On an individual variant basis, this is partly due to the
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variability in allele frequencies that exist between populations of different ethnicity. For
example, the lead SNP from the UBE2E2 locus (rs6780569) has a reported minor allele
frequency (MAF) of ~9% in Europeans, however, the same variant has a MAF of ~22%
in East Asians (Fu et al., 2011). With a lower MAF, larger sample sizes are required in
order to maintain adequate statistical power thus variability in allele frequency may
confound the ability to replicate an association in ethnically diverse populations.
Accordingly, the lead SNP from UBE2E2 was associated with T2D in East Asians
(P=1.0x10-9) but was not replicable in Europeans (P=0.98) (Yamauchi et al., 2010).
Although statistical power limitations in our study prevent the ruling out of associations
between top T2D variants and aboriginal T2D susceptibility, it may be expected that the
established T2D variants may vary in effect size or frequency in Canadian aboriginal
populations.

Lastly, limited data on our participants’ relatedness to other participants within
each aboriginal sample prevented adjustment for any inflation in association signal due to
common ancestry. The inclusion of multiple closely related participants in either cases or
controls may inflate allele frequencies simply due to relatedness and not due to T2D
susceptibility. This effect may also confound quantitative trait analysis as closely related
participants may cluster at either end of a quantitative trait spectrum. Future studies must
carefully document family structures and relatedness within aboriginal populations
especially as these populations are likely to be small with low net migration into these
communities.
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In summary, we have demonstrated that the top GWAS-identified T2D-associated
variants were not associated with T2D susceptibility in a sample of Canadian aboriginals.
We also demonstrated, through a composite GRS that aboriginal T2D patients did not
carry a significantly higher burden of T2D-associated variants compared to controls. One
variant in HMG20A was associated with FBG in aboriginals of Inuit descent; however,
this observation requires further replication in larger cohorts. Due to the power
limitations of our study, the findings reported here have not ruled out the potential role
for genetic variation at these established loci in modulating T2D susceptibility and
glycemic traits in aboriginal populations. Further studies involving larger aboriginal
cohorts with well-documented information on relatedness will contribute towards the
ongoing investigation of T2D determinants amongst Canadian aboriginal populations and
will provide a more conclusive assessment of the degree of overlap between Europeanand South Asian-identified T2D variants in aboriginal populations.
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CHAPTER 5

DISCUSSIONS AND CONCLUSIONS

5.1 Genetic characterization of complex disease

Over the past decade, our concept of genetic predisposition to complex disease has
rapidly gained depth. As a result of the efforts of international consortia such as the
Human Genome Project and the International HapMap Project (International Hapmap
Consortium, 2003), the map of common genomic variation has enabled a leap forward to
high-resolution genome-wide association studies (GWAS). At the time of this thesis
work, the GWAS approach was established as a versatile and effective tool for
discovering novel disease susceptibility loci and validating candidate loci based on the
frequencies of common variants. Combined with targeted resequencing, findings from the
GWAS era have provided new perspectives on complex disease susceptibility and have
also supported re-evaluation of current concepts of complex disease genetics.

The studies presented within this thesis reflect application of the current
established techniques to characterize the genetics of complex disease susceptibility.
Using candidate gene resequencing, the GWAS approach and targeted genotyping of
GWAS-identified variants, we have demonstrated the application of modern genetic
approaches to investigate complex diseases relating largely to cardiovascular disease
(CVD). We implemented these techniques via 1) a candidate gene resequencing study in
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circumpolar Inuit populations that revealed private, common missense variants within the
low-density lipoprotein receptor (LDLR) gene; 2) the most comprehensive genomic
analysis of a pre-dementia phenotype known as “cognitive impairment, no dementia”
(CIND) utilizing cardio-metabolic and Alzheimer disease (AD)-associated variants; and
3) a type 2 diabetes (T2D) candidate variant analysis in North American and Greenland
aboriginals based on T2D GWAS meta-analyses. Cumulatively, these studies recapitulate
the current molecular genetics techniques and analytical approaches widely utilized in
order to assess the role of common variation on disease susceptibility and phenotypic
variability.

5.1.1 p.G116S in LDLR is associated with LDL-C among the Inuit
We have reported the private, common p.G116S and p.R730W variants in LDLR within
five circumpolar Inuit populations. Furthermore, we showed that G116S was robustly
associated with a large effect on plasma low-density lipoprotein cholesterol (LDL-C)
while p.R730W showed a modest non-significant effect on LDL-C (Table 2.4). Although
our statistical analyses have implicated p.G116S as having a considerable effect on
plasma LDL-C concentration, additional biochemical experiments are required in order to
establish causal mechanisms underlying the observed p.G116S association with higher
LDL-C. As follow-up experiments, we will investigate the effects of either LDLR variant
on LDLR expression as well as receptor activity.

Our findings regarding p.G116S and p.R730W have provided new insight into the
unique genetic architecture of Inuit descendants as well as potential CVD risk factors
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exclusive to the Inuit. As LDLR has been well-established in cholesterol homeostasis, we
applied direct Sanger sequencing of LDLR coding regions to test for the presence of
coding variants associated with plasma LDL-C. Interestingly, the variants p.G116S and
p.R730W were observed with relatively high frequencies (5%-17%) across five distinct
Inuit samples (Table 2.1, Figure 2.1). In line with the fact that LDLR is a major
regulator of LDL-C homeostasis, we replicated independent associations between mean
LDL-C and p.G116S or p.R730W carrier status in a combined Inuit cohort (Table 2.3A).
These findings were further explored by using multivariate linear regression to test a
dominant genetic model based on either p.G116S or p.R730W status which further
supported association between p.G116S and LDL-C (Table 2.4). Importantly, p.G116S
was consistently associated with raising LDL-C within each Inuit population with a
summary effect size of ~0.54 mmol/L per allele dose in a combined Inuit cohort while
p.R730W was non-significantly linked with a modest lowering of LDL-C by ~0.05
mmol/L per allele dose (Table 2.4). The effect of p.G116S on LDL-C is intriguing as
common variants are not usually associated with such large effect sizes. The top LDL-Cassociated common variants from GWAS meta-analyses near SORT1, APOE and LDLR
were reported with per-allele effect sizes of 0.15 mmol/L, 0.18 mmol/L and 0.18 mmol/L
respectively (Table 2.6) (Teslovich et al., 2010). Furthermore, p.G116S homozygotes do
not have the severe LDL-C phenotypes characteristic of homozygous familial
hypercholesterolemia in which patients have plasma LDL-C concentrations 6-10 fold
normal concentrations (Liyanage et al., 2011). In this context, the effect size associated
with p.R730W is relatively agreeable with the observed relationship between variant
frequency and effect size (Figure 2.5). p.R730W is also of interest particularly as the vast
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majority of LDLR missense variants have been associated with hypercholesterolemia with
only one LDLR variant previously linked with LDL-C lowering (Boright et al., 1998).
Ultimately, this study has established the association between p.G116S and LDL-C. The
effect of either variant on LDLR function as well as the association between the
respective effects on LDL-C and CVD-related end-points such as myocardial infarction
remains to be determined.

5.1.2 Cardio-metabolic and AD variation in “cognitive impairment, no dementia”
We have described the most comprehensive genetic analysis of the common predementia phenotype known as CIND (Dube et al., 2013). Using the Cardio-Metabochip
genotyping array, we utilized a “next-generation” approach to investigate the frequency
of genomic variants linked with cardio-metabolic traits in CIND patients and controls
(Voight et al., 2012). Although we replicated a potential association between CIND and
rs1439568 in the ZNF608/GRAMD3 locus on chromosome 5 (Table 3.3), we did not
observe strong evidence linking cardio-metabolic variation in CIND. We also sought to
investigate the potential association between established non-ApoE AD-associated
variants and CIND. Although no associations were identified, we did replicate similar
effect sizes as those previously reported for variants in CR1, ABCA7, and PICALM
(Table 3.4). Given that our sample size was a small fraction of the large cohorts metaanalyzed in AD GWAS, it is likely that low statistical power hindered our ability to
detect small yet significant effect sizes. In order to partly address the issue of limited
power, we assessed the accumulation of multiple AD risk alleles in CIND patients
compared to controls using a genetic risk score (GRS) utilizing the 11 non-APOE AD-
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associated variants. Comparable AD-GRSs between CIND patients and controls did not
support a role for non-ApoE AD-associated variants as determinants of CIND status.
Lastly, we investigated the frequency of the APOE E4 isoform in CIND patients as the
E4 isoform remains the strongest genetic determinant of AD. The modest association
between the E4 isoform and CIND status compared to controls (OR=1.35, P=0.044,
Table 3.5) did not provide robust evidence for the E4 isoform as a marker of CIND;
however, a previous study identified a 2.7- to 5-fold increase in AD progression from
CIND in E4 carriers (Hsiung et al., 2004; Tuokko et al., 2003). In summary, our findings
did not support a strong correlation between common cardio-metabolic and ADassociated variants in CIND susceptibility. The phenotypic heterogeneity inherent in
CIND, however, is likely to continually confound further genetic analyses unless predementia patients can be better stratified based on the disease underlying the observed
cognitive phenotype.

As no previous studies investigated genetic determinants of CIND or related mild
cognitive phenotypes with the exception of APOE E4 carrier status, we sought to
investigate the role of genetic variation in CIND based on the two most common diseases
leading to dementia which remain AD and vascular dementia (VaD). As VaD- and ADrelated mechanisms account for the majority of dementia cases among the elderly, we
hypothesized that common variants previously associated with cardio-metabolic traits
and AD risk were also associated with CIND. The use of the Cardio-Metabochip was
essential in testing the former part of this hypothesis by facilitating targeted genotyping
of common variation at genome-wide loci associated with VaD-related traits. This type of
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trans-disciplinary application represented a novel approach to studying cognitive health
and may be applicable to the study of similar diseases affecting cognition. In testing the
latter hypothesis that AD-associated variation is also associated with CIND, we
developed a panel of 11 AD-associated variants based on the largest AD GWAS metaanalyses (Hollingworth et al., 2011; Naj et al., 2011). The targeted approaches utilized
here have represented a multi-disciplinary approach that has not been widely
implemented but is likely to gain support as it has become increasingly evident that many
cognitive disorders share similar genetic risk loci (Cross-Disorder Group of the
Psychiatric Genomics Consortium, 2013). Ultimately, our study provided a preliminary
yet comprehensive assessment of genetic determinants of CIND and also highlighted
some of the issues involved in studying a pre-clinical cognitive phenotype that must be
considered in future analyses of pre-clinical dementia.

5.1.3 Type 2 diabetes-associated common variation in aboriginal populations
We have demonstrated that T2D-associated variants from European and South-Asian
populations are also common among aboriginal Canadians and Greenlanders but are not
clearly associated with T2D susceptibility. North American aboriginal populations
continue to experience significant socio-cultural change and a generally accepted
indicator of increasing “Westernization” has been the rapid increase in T2D frequency
among aboriginal North Americans. We therefore sought to investigate the frequencies of
the top GWAS-identified T2D variants from European and South-Asian cohorts in order
to assess whether putative T2D loci are also applicable within aboriginal populations
(Table 4.3). Our test for association between T2D variants and T2D status within the
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Sandy Lake Oji-Cree and Inuvik Inuit did not reveal strong correlations, however, this
analysis was limited by both the sample size and the small effect sizes attributed to each
variant regarding T2D risk (Table 4.5). We also tested for association between the T2D
variants and variability in fasting blood glucose (FBG) within three populations of Inuit
descent which revealed a modest association between the rs7178572 variant near
HMG20A on chromosome 15 in a combined analysis (Table 4.6). We further assessed
the accumulation of multiple T2D variants through a T2D GRS (Table 4.7). While mean
GRS based on all 17 selected variants or only European-identified variants were similar
between T2D patients and controls, we observed a nominally significant difference in
mean GRS between Inuvik T2D patients and controls based on South Asian-associated
variants. Cumulatively, these analyses did not provide a strong indication that established
T2D variation is associated with T2D among aboriginals. However, we have provided a
first look into the frequency and effect sizes of European- and South-Asian-identified
T2D-associated variation as it applies to aboriginal Canadians and Greenlanders.

Similar to our approach for studying CIND genetics, we utilized large-scale
GWAS meta-analyses to identify a panel of the top T2D-associated variants. This
approach allowed us to focus our investigation on established T2D loci which was the
most feasible means for assessing genetic T2D risk amongst aboriginal populations given
limited sample sizes. Thousands of T2D patients and controls from homogenous sample
populations were required in order to identify genome-wide significant associations
between common variants and T2D as well as T2D-related phenotypes. As no analogous
aboriginal cohorts exist that would adequately power the discovery of additional T2D-
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associated variants, our alternate approach took advantage of the wealth of T2D GWAS
data to propose candidate loci. To further address the issue of limited sample size, we
combined aboriginal populations of common descent when investigating FBG among the
Inuit. A similar approach may be required in future genetic studies within aboriginal
populations in order to improve sample size and statistical power.

An additional consideration for our study related to the investigation of common
variation in multi-ethnic cohorts. A fundamental requirement for GWAS involves the use
of homogenous study populations which is usually addressed in part by stratification
based on ethnicity. Replication of GWAS results in additional multi-ethnic cohorts
represents a key step in confirming potential gene-disease associations. In addition to our
study limitations, further ethnicity-specific factors have been hypothesized to affect
replicability in multi-ethnic association studies using common variants. These factors
may include gene-gene and gene-environment interactions but ethnicity-specific patterns
of linkage disequilibrium are believed to largely account for the discrepancies observed
in multi-ethnic association studies (Fu et al., 2011; Ioannidis et al., 2004; Lanktree et al.,
2009; Lin et al., 2007). While the more pertinent limitations of our study involved issues
of sample size, future genetic studies aimed at replicating associations in aboriginal
populations must consider the role of ethnicity-specific patterns of linkage disequilibrium
as a potential confounding factor.
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5.2 Current methodological limitations

The most significant limitation hindering genetic studies of complex disease relates
fundamentally to the uncertainty surrounding the concept of complex disease genetics.
Based on GWAS results from recent years, the portion of complex disease heritability
explained by common variation has fallen short of what was initially expected as outlined
in the “common disease-common variant” (CDCV) hypothesis (Reich and Lander, 2001).
Furthermore, the tendency of GWAS to identify variants localized in gene deserts and
intronic or intergenic regions has complicated the translation of robust association signals
to biological relevance or clinical utility. Accordingly, new hypotheses have recently
emerged that aim to account for the “missing heritability” in complex disease
susceptibility that GWAS has failed to uncover. These hypotheses have largely supported
the pooling of GWAS data for large-scale meta-analyses, a shift towards investigating the
role of rare variation in complex disease susceptibility, and further in vitro and in vivo
modeling of variants.

5.2.1 The CDCV hypothesis then and now
As previously discussed, the CDCV hypothesis provided the first generally accepted
concept for the role of common variation in common, complex disease susceptibility. As
the CDCV model began to formulate in the late 1990’s, it was believed that the
anticipated catalogue of common human genomic variants would be used to perform
hundreds of thousands of association tests in what became known as GWAS. A decade
since the initial draft human genome release, GWAS have been applied to virtually every
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common complex disease and the overall results were not quite as definitive as expected.
As GWAS have unanimously revealed, associated variants individually contribute
modestly to disease risk across almost all complex diseases. Combined analyses
involving the top GWAS hits from multiple loci for a disease, in the form of risk scores,
still only explain a modest percentage of disease heritability. The portion of complex
disease heritability left unexplained by common variation has been dubbed the “missing
heritability” (Manolio et al., 2009). Based on the small effect sizes assigned to associated
variants as well as the stringent Bonferroni-corrected significance thresholds required
when performing >106 tests for association, GWAS require thousands of carefully
phenotyped cases and controls in order to support the likelihood of detecting association.
Despite validating candidate disease loci as well as identifying many novel and
unexpected risk loci, the hunt for the “missing heritability” has come to dominate the
continued effort to understand complex disease etiology.

Going forward, the lessons learned from GWAS must be utilized to re-assess and
improve the current working model of complex disease genetics. Due largely to the issue
of missing heritability, the CDCV hypothesis has recently been revisited and refined.
Two main approaches have been described which focus on the continued search for
common variant associations and on the role of rare variation in complex disease
susceptibility. The potential remains for additional undiscovered common variants of
subtle effect to contribute to disease susceptibility but it is believed that GWAS have
simply been underpowered to detect these associations. Targeted genotyping and
resequencing efforts have been proposed to help reveal additional common variants while
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lowering the stringent statistical requirements typical of GWAS by focusing on select
genomic loci. Similarly, meta-analyses of GWAS data are also likely to reveal previously
undetected associations due to increased sample sizes and statistical power. Alternatively,
it is also hypothesized that GWAS-identified variants are tagging low-frequency variants
– the type that are excluded from GWAS – through linkage disequilibrium. These rare
variants, of minor allele frequency <1%, are thought to have greater effects on disease
susceptibility and may contribute to the “missing heritability” puzzle. While these
approaches aim to account for the “missing heritability”, it has also been suggested that
the total heritability ascribed to a disease may be overestimated. By failing to account for
gene-gene or epistatic interactions, total heritability estimates may actually be inflated
and thus create “phantom heritability” that cannot be explained by the discovery of
additional variant associations (Zuk et al., 2012). A general road map for the future of
genomics in complex disease investigation has thus been proposed, however, the extent
to which these approaches will address current limitations remains to be observed.

5.2.2 Clinical translation of GWAS findings
A commonly discussed limitation involves the lack of clinical utility in GWAS results.
As GWAS-identified variants currently explain a small proportion of disease risk or
phenotypic variability, it has been difficult utilizing GWAS findings to help identify
high-risk individuals or to re-classify at-risk patients. Although this is a significant
limitation for the immediate application of GWAS results, the true worth seems to lie in
the ability for GWAS to nominate disease-associated loci. Identifying the genes involved
in disease pathogenesis may prove to be just as important as the discovery of a high-risk
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variant as detailed understanding into disease mechanisms and the biological players
involved will facilitate the development of therapeutic strategies. To appreciate this
concept, one may look no further than the example of the targeted inhibition of 3hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) by statin therapy. As HMGCR is
the rate-limiting enzyme in endogenous cholesterol synthesis, its inhibition markedly
lowers plasma LDL-C and significantly lowers CAD risk (Brugts et al., 2009). Common
variation at the HMGCR locus has been associated with a modest effect on plasma
cholesterol yet inhibition of this key enzyme has shown profound effects on cholesterol
homeostasis which have translated to cardiovascular benefits. Similarly, the GWASidentified sortilin gene, encoded by SORT1, has been revealed as a novel receptor
involved in LDL-C homeostasis and suggests a potential therapeutic target. As many
common complex diseases have been associated with multiple loci through GWAS metaanalyses, the monumental task of investigating the explanation underlying these
association signals is currently underway. Thus the clinical value of GWAS may be
forthcoming as disease etiology is better understood.

5.2.3 An end to the GWAS era?
With many common complex diseases now investigated by the >1400 published GWAS,
the need for the execution of additional GWAS has been questioned largely on the
grounds that 1) multi-ethnic GWAS data now exist for many common complex diseases
such as CVD and AD; 2) existing GWAS datasets must be investigated for biological
relevance; and 3) next-generation genotyping platforms have been designed for enriched
genotyping of variants in candidate loci or exonic regions based on GWAS meta-analyses
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which will permit more direct hypothesis testing. Much remains to be investigated
through association studies; however, the traditional GWAS approach must be adapted to
the evolving concept of genetic susceptibility in complex disease etiology in a manner on
pace with the continued development of the CDCV hypothesis.

5.3 Future directions for genomic analyses of complex disease

As better characterization of the current unexplained heritability will be investigated
through assessment of rare variation, a variety of strategies – both novel and established
techniques – are likely to become increasingly important to future genomic studies of
complex disease. The increasing feasibility of next-generation sequencing (NGS)
platforms has made whole genome and exome sequencing more accessible where NGS is
expected to become the new standard approach in variant discovery. Established
approaches such as studies using population isolates, monogenic disease phenotypes and
investigations into the extremes of quantitative trait distributions also remain viable
strategies in the discovery of susceptibility loci. More experimental approaches may also
prove insightful such as the use of pre-clinical mouse models to nominate candidate loci
in human diseases. Together, this range of techniques promises to help better characterize
the genetic architecture underlying complex disease susceptibility.

5.3.1 Next-generation sequencing
As only ~10% of common variation is assessed using GWAS panels through the use of
SNPs (Willer and Mohlke, 2012), whole genome and exome sequencing have become
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increasingly implemented for the utility offered by the comprehensive assessment of
genomic variation. Due to the costs of NGS, current applications have been limited in
sample size relative to GWAS. As a result, a two-stage study design has emerged as a
common workflow. First, small discovery cohorts of cases and controls are sequenced
and all genetic variants are identified. The subsequent partitioning of variants based on
frequency or genomic position can be used to nominate candidate variants for genotyping
in a larger replication cohort (Kang et al., 2012). Alternatively, exome sequencing offers
a focused approach to sequencing only protein-coding regions of the genome where
variation may be more likely to have deleterious effects.

The recent discovery of a novel large-effect AD-associated variant in the TREM2
gene independently by two groups illustrates the potential for NGS-based association
studies. Using NGS in a case-control design, Guerreiro et al. were able to target loci
harbouring a significant accumulation of rare variants which were then replicated in
publicly available GWAS datasets (Guerreiro et al., 2013). Jonsson et al. independently
identified the novel AD-associated variant in TREM2; however, this was accomplished
by first comprehensively characterizing genetic variation in a genetically homogeneous
Icelandic population (Jonsson et al., 2013). As described earlier, the use of population
isolates in association studies represents an established approach which limits genetic
heterogeneity and improves statistical power (Tian et al., 2008). These workflows are
likely to represent a recurring strategy applied in future NGS-based studies of complex
diseases and are summarized in Figure 5.1.

160

Figure 5.1 Investigating rare variation in complex disease. Using recent rare variation
studies in AD as a template (Guerreiro et al., 2013; Jonsson et al., 2013), a common
workflow is emerging for studying the role of rare variation in complex disease. A) Nextgeneration sequencing (NGS) of the whole genome or the exome is used to
comprehensively identify genomic variation. This is performed in a small number of
participants or cases and controls as a variant discovery phase. B) Variation can be
investigated agnostically by scanning the entire genome or using a hypothesis-driven
approach where candidate loci may be prioritized as sites believed to be harbouring a
burden of variation. C) Rare variants are selected based on allele frequency (MAF<1%).
Association analyses begin with a gene-based approach where the accumulation of rare
variants at a given gene or locus is compared between cases and controls. In this
example, AD cases had a significantly higher accumulation of rare variants in TREM2
versus controls. Closer investigation revealed that the R47H variant was associated with
AD status. D) Using publicly available AD GWAS datasets, genotyping data on millions
of common genomic variants can be used to replicate associations discovered using NGS
through the direct genotyping of the variant of interest or through imputation. E) A final
estimate of the variant effect size and frequency can be determined by combining all
datasets into a single statistical analysis or meta-analysis.
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On the clinical side, NGS has proven useful in helping to diagnose patients with
suspected genetic disorders when candidate re-sequencing approaches have failed. For
example, Rios et al. used whole genome sequencing to correctly identify the diseasecausing mutations underlying an 11-month-old girl’s sitosterolemia after being
misdirected by an initial presentation of hypercholesterolemia (Rios et al., 2010). In an
analogous case, exome sequencing helped elucidate the causal variant underlying AD in a
patient from a consanguineous family when candidate sequencing of known ADassociated genes including APP, PSEN1 and PSEN2, failed to identify potential diseasecausing variants (Guerreiro et al., 2012). The subsequent exome sequencing ultimately
identified a variant in NOTCH3 which was previously associated with cerebral autosomal
dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL);
the most common hereditary form of stroke (Joutel et al., 1996). Instances of NGS
approaches applied to solving unusual clinical cases have become increasingly reported
as the comprehensive nature of genome-wide sequencing provides clinicians with
unprecedented insight into genetic disease pathogenesis and ultimately improved
diagnostic capability.

5.3.2 Lessons from monogenic diseases and extreme phenotypes
Linkage studies of monogenic disorders established the sufficiency of a single deleterious
variant to cause remarkable phenotypes such as LDLR mutations in FH patients. By
elucidating the susceptibility loci in monogenic diseases, we gain a fundamental insight
into the biological pathways involved in modulating disease susceptibility and phenotypic
variability that can be applied to patients with less severe but unhealthy phenotypes.
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Combining the study of monogenic disorders with emerging genomic technologies, it will
be possible to uncover candidate loci that have eluded GWAS but nonetheless may have
a profound phenotypic effect if perturbed. Furthermore, the process of identifying disease
variants has become streamlined with the usage of NGS platforms as investigation is no
longer limited to candidate loci but now incorporates the majority of genomic variation
(Gilissen et al., 2012). Another emerging approach involves the dichotomizing of
quantitative traits by sampling disease-free participants that occupy the tail-ends, or
extremes, of trait distributions. While GWAS have been applied to the extremes of
phenotypic distributions, NGS approaches have not been widely utilized in this respect
and may offer new insight into the genetic architecture and biological pathways involved
in modulating phenotypic variability (Barnett et al., 2012).

5.3.3 Mouse disease models and candidate susceptibility loci
Model organisms, particularly murine models, play a key role in the development of
therapeutic strategies and are often utilized in identifying the effects of treatment in
complex disease models (Welch, 2012). Alternatively, murine models can also be used to
identify novel loci in complex human diseases. Studies using congenic mapping
approaches in mice expressing a human disease phenotype such as atherosclerosis or
hypertriglyceridemia have successfully implicated mouse susceptibility loci in human
disease. Gargalovic et al. identified an association between variation in the Zhx2 gene
with plasma lipid metabolism using a congenic mapping technique; a locus that had not
previously been implicated in human lipid metabolism (Gargalovic et al., 2010).
Interestingly, a subsequent GWAS meta-analysis on carotid intima media thickness (C-
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IMT), a measure of subclinical atherosclerosis, revealed an association with ZHX2 which
proposed the potential use of mouse genetics to better understand the genetic architecture
of complex phenotypes in humans (Bis et al., 2011). Using a different approach,
Johansen et al. showed that patients with polygenic hypertriglyceridemia (HTG) carried a
significant burden of rare variants at GPIHBP1 and LMF1 which were first associated
with murine HTG phenotypes (Johansen et al., 2012). Thus the application of mouse
genetics in identifying novel susceptibility loci in humans may prove effective in the
investigation of additional complex phenotypes.

5.4 Personalized medicine and therapeutic strategies

In brief, the concept of personalized medicine has centered on the design and
implementation of health care tailored to the individual patient’s unique biological and
genetic components. With the increasing feasibility of whole genome sequencing, there
has been growing anticipation surrounding the idea that genomic data will facilitate
improved patient care in the near future. The incomplete understanding between genotype
and complex disease risk, however, remains the greatest limiting factor in the integration
of genomic data for the improvement of personalized medicine. Despite this limitation,
GWAS and emerging genomic techniques have impacted upon the current concept of
personalized medicine and have shed new light on future genomic applications in
personalized medicine. GWAS have undeniably helped to advance the concept of
personalized medicine as well as the field of pharmacogenomics and drug design which
has suggested that the legacy of GWAS has yet to be fully realized.
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5.4.1 Personalized medicine in the genomics era
The formation of risk scores based on GWAS findings served as an initial attempt at
validating a role for common variants in assessing patient risk. Aggregate scores of riskassociated alleles from the top GWAS-identified variants associated with a specific
phenotype were calculated in order to assess the genetic risk burden within the patient.
These risk scores were then tested in independent cohorts of patients with related
phenotypes in order to validate the clinical utility of such risk scores with the intention of
incorporating genetic information within traditional risk algorithms such as the
Framingham Heart Score. Modest success has been attributed to genetic risk scores that
assess complex disease risk including CVD and AD (Kathiresan et al., 2008; RodriguezRodriguez et al., 2012). In one relatively successful study, Kathiresan et al. showed that a
GRS of 9 variants associated with LDL or HDL cholesterol was an independent risk
factor for incident CVD, however, genotype score did not improve clinical risk prediction
(Kathiresan et al., 2008). Associations between GRS and a given phenotype have been
commonly reported, however the limited ability for GRS to substantially reclassify at-risk
patients has largely dissuaded the clinical utility of genetic risk prediction in the general
population (Jostins and Barrett, 2011). Due to the small effects on risk that are ascribed to
GWAS-identified loci, it may not be surprising that panels of small-effect variants do not
significantly improve patient risk prediction. With genomic studies shifting from
common variation toward rare variation, the identification of rare variants with
potentially larger effects on risk may be more suited for clinical utility in calculating
complex disease risk in the patient.
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As our understanding of the genetic determinants of complex disease progresses,
it will become increasingly pertinent to assess the patient’s predisposition to disease at
the earliest time point which is commonly perceived to be in utero. Prenatal genomic
analysis represents a rapidly developing field within personalized medicine where the
assessment of disease susceptibility may begin during fetal development (Bianchi, 2012).
Until recently, prenatal diagnostic techniques were limited to ultrasonography and fetal
metaphase karyotyping. The more sophisticated analyses used today have incorporated
DNA micro-array-based assays implemented in conjunction with karyotyping to identify
high-risk chromosomal abnormalities. Historically, however, fetal health has largely been
based on morphological factors and low-resolution genetic analyses. The recent
discovery that the fetal genome can be sequenced non-invasively from maternal blood
has opened the door for prenatal screening techniques that utilize current and developing
genomic technology (Fan et al., 2012). Sequencing of the fetal genome offers variant
detection at the highest resolution and thus provides the means for identifying potentially
deleterious point mutations. The utility of this information in personalized medicine
theoretically has great potential. The effectiveness of this strategy is ultimately dependent
upon our ability to interpret variation as being deleterious or benign. Thus the quick
succession of technological advances in genetics has made it easy for our reach to exceed
our grasp in terms of the ability to generate data but the limitation in using the data for
clinical decision-making.
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5.4.2 Defining the “genomics” in pharmacogenomics
Heterogeneity in patient response to drug treatment remains a major complication in
delivering cost-effective health care. While trial-and-error may be used for some drugs in
order to identify the optimal dosage for the patient, this process is imprecise, costly,
ineffective if the patient cannot metabolize the drug, and potentially hazardous. The
genetic component underlying the variability in drug response has long been suspected,
however the genomic techniques described here have only recently been established in
studies on heterogeneity in drug response as well as susceptibility to adverse reactions.
As with the study of complex phenotypes, candidate gene studies provided the first albeit
limited investigations into genetic determinants of variable drug response from which the
term pharmacogenetics was coined. GWAS have helped expand the concept of the
genetic architecture underlying drug response while next-generation approaches such as
whole-genome and exome sequencing are poised to provide even greater detail regarding
the genetic components involved in modulating pharmacologic effects.

Statin therapy (3-hydroxy-3methylglutaryl-coenzyme A reductase [HMGCR]
inhibitors) represents a prime example of a drug treatment that has become better
understood through modern genomic approaches. Despite their status as the standard drug
treatment for lowering LDL-C and thus cardiovascular risk, statin-mediated LDL-C
lowering can vary as much as 10% to 70% in the case of rosuvastatin (Simon et al.,
2006). Accordingly, an important future goal for the prescription of statin drugs has
focused on the identification of genetic factors that may help in determining the optimal
statin and drug dosage tailored to the patient. Candidate gene studies importantly
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identified a common haplotype in HMGCR encoding an alternatively spliced gene
product associated with reduced LDL-C response to simvastatin (Krauss et al., 2008).
Subsequent candidate gene studies and GWAS implicated several additional loci which
helped characterize pathways relevant to statin pharmacodynamics (Chasman et al., 2012;
Voora and Ginsburg, 2012). Although association signals have been reported at PCSK9,
ABCG2, LPA, the most consistent findings have associated APOE isoforms with variable
statin-mediated LDL-C response; carriers of the E2 isoform are associated with the
greatest LDL-C lowering followed by E3 and E4 isoforms (Voora and Ginsburg, 2012).
Although these findings have not yet translated to changes in the process of statin
prescription, GWAS have importantly identified some of the biological players and
pathways involved in statin uptake and efficacy which will inform future drug design.

Genomic approaches may also benefit studies on adverse drug reactions (ADRs).
Again, GWAS on statin myopathy, or muscle pain and weakness due to statin therapy
(Thompson et al., 2003), successfully identified a robust association between common
variation at the SLCO1B1 gene and statin myopathy susceptibility (OR=16.9; 95%
CI=4.7-61.1) (Link et al., 2008). Despite suggestions from the Food and Drug
Administration as well as the Clinical Pharmacogenetics Implementation Consortium to
institute clinical genotyping of SLCO1B1 variants to assess patient risk, statin myopathy
risk continues to be largely managed using trial-and-error and monitoring of serum
creatine kinase levels (Wilke et al., 2012). Further examples of the potential benefit of
pharmacogenomics in ADR studies abound (Harper and Topol, 2012). For instance,
prospective screening of the HLA haplotype HLA-B*5701 in patients taking abacavir, an
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inhibitor of human immunodeficiency virus (HIV) reverse transcriptase, was shown to
reduce the frequency of abacavir-related hypersensitivity reactions from 3% to 0%
(Mallal et al., 2008). As studies continue to make a strong case for the integration of
pharmacogenomics in patient care, it seems increasingly plausible that genomic data will
have a greater role in determining safe and effective drug dosage.

The next stage for pharmacogenomics is likely to involve greater utilization of
exome or whole genome sequencing for the identification of rare variants that cannot be
tested for association using traditional GWAS methods. As pharmacogenomics studies
using NGS have yet to be published, we can only speculate on the potential for NGS to
advance pharmacogenomics. However, large-scale resequencing studies have provided
some insight into what may be expected from next-generation studies. One resequencing
study by Nelson et al. reported an abundance of rare variation in 202 genes encoding
drug targets where rare variants were observed in ~1 in every 17 bases (Nelson et al.,
2012). Additionally, Ramirez et al. reported an abundance of rare variants in patients
with drug-induced long QT syndrome (diLQTS) at loci associated with congenital
arrhythmia syndrome suggesting that rare variation at known arrhythmia loci plays a role
in diLQTS predisposition (Ramirez et al., 2012). Analogous results may be expected
when next-generation methods are further integrated into pharmacogenomics, however
the transition from variant discovery to clinical incorporation remains contested.
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5.4.3 Pharmacological design
GWAS and resequencing studies may also prove to be powerful tools in the complicated
process of drug design. As discussed, GWAS have provided valuable insights into the
genetic component underlying many common and complex diseases thus improving our
concept of the biological pathways implicated in any given complex disease. By
modulating gene expression at GWAS-identified susceptibility loci, it may be possible to
produce a potentially therapeutic effect. Currently, the technologies exist whereby small
molecule inhibitors, anti-sense oligonucleotides (ASOs) and gene replacement can
effectively target and perturb gene expression and have already been incorporated in
emerging therapeutic strategies.

The leading-edge of dyslipidemia therapies is represented by a host of novel
treatment strategies that each utilizes pharmacologic technologies. Lomitapide, a small
molecule inhibitor of microsomal triglyceride transfer protein (MTTP), was developed as
a cholesterol-lowering therapy that recently received FDA approval for the treatment of
homozygous familial hypercholesterolemia (Cuchel et al., 2007). Mipomersen, another
cholesterol-lowering therapy, is an ASO designed to hybridize to and degrade apoB
mRNA thus reducing expression of apoB expression and, subsequently LDL cholesterol
(Ricotta and Frishman, 2012). Advances in viral gene transfer technologies have led to
breakthroughs in gene therapy research. Alipogene tiparvovec represents the first gene
therapy approved for marketing in Europe for the treatment of familial lipoprotein lipase
deficiency (LPLD) (Dube and Hegele, 2012). LPLD patients lack a fully functional copy
of lipoprotein lipase (LPL) thus alipogene tiparvovec partially restores functional LPL
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through transient transduction by viral particles containing a functional copy of human
LPL (Dube and Hegele, 2012). The emerging gene therapies have been well-suited to
treating monogenic disorders. In translating gene therapy to complex polygenic diseases,
however, the difficulty remains with identifying the ideal genomic targets which will
require deciphering the biological relevance of the top GWAS genes.

5.5 Conclusions

Genetic studies of complex human disease are set to undergo a dramatic shift in both the
technological and analytical approaches used to evaluate genetic risk. The studies
described here encapsulate the current techniques that have been utilized to develop and
test our current understanding of genetic susceptibility to common and complex disease.
We have demonstrated 1) a candidate gene resequencing study in which the private
common LDLR variant G116S was associated with plasma LDL-C among Inuit
descendants; 2) the design and execution of a targeted GWAS investigating the role of
cardio-metabolic and AD-associated variation in pre-dementia susceptibility; and 3) a
candidate genotyping study of T2D-associated GWAS variants in aboriginal Canadian
and Greenlander populations. Collectively, these three studies represent the established
techniques implemented in assessing the genetic architecture underlying complex
phenotypes. Utilizing these techniques, we have contributed new insight into the genetic
component underlying plasma LDL-C concentration and cognitive decline as well as the
frequency of T2D risk alleles in aboriginal Canadians. With the emergence of NGS, rare
variant analysis has come to represent the shift in focus with the aim of accounting for
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some of the disease heritability left unexplained by GWAS. The next chapter in the
genomic study of human disease will undoubtedly require a new set of analytical
procedures, however the lessons learned from both classical genetics and the recent
CDCV hypothesis-driven era have been invaluable in establishing a concept of genetic
risk in complex disease upon which we can continue to build.
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